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ABSTRACT 
Pro-inflammatory and atherogenic stimuli up-regulate the expression of endothelial 
adhesion molecules which support the extravasation of leukocytes into the sub-
endothelial space. This process drives plaque progression and contributes to its 
complications. Erg is an ETS transcription factor constitutively expressed in EC 
which regulates angiogenesis and endothelial homeostasis. Recently, Erg was shown 
to inhibit endothelial expression of the chemokine IL-8. In EC, Erg expression is 
down-regulated by the pro-inflammatory cytokine TNF-alpha, through a mechanism 
which appears to involve Erg protein degradation. These data suggest that Erg may 
be involved in inflammation. To test this hypothesis, I modulated Erg expression in 
HUVEC by inhibition with antisense or over-expression using adenovirus encoding 
for Erg (AdErg). Basal ICAM-1 expression was up-regulated following Erg 
inhibition, and down-regulated by Erg over-expression. Both of these effects were 
transcriptional, as shown by a luciferase reporter assay. Over-expression of Erg could 
inhibit TNF-dependent up-regulation of ICAM-1 and ICAM-1 promoter activity. 
Thus Erg acts as a transcriptional repressor of ICAM-1 expression in resting and 
activated EC. This pathway involves NF-kB, since both basal and TNF-α-induced 
NF-kB activity was repressed by AdErg, and Erg over-expression inhibited the TNF-
α induction of NF-kB p65 phosphorylation. In vitro, Erg over-expression led to 
decreased adhesion of leukocytes to TNF-stimulated HUVEC. In vivo, local injection 
of AdErg in the mouse paw resulted in reduction of TNF-α-induced inflammation.  
Interestingly, staining of human coronary artery plaques showed that Erg is absent 
from activated endothelium over the vulnerable region of the plaque. In conclusion, I 
propose that Erg exerts a protective role in the endothelium by repressing pro-
 4 
inflammatory signaling and gene expression. These results suggest a novel approach 
to anti-inflammatory therapies. 
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CHAPTER 1: INTRODUCTION  
 
1.1 Physiologial and pathological outcomes of inflammation 
Inflammation is a response of the organism which is initiated by injurious stimuli, as 
infective agents or tissue damage. Acute inflammation is characterized by a quick 
transmigration of leukocytes and leakage of protein exudate from the blood stream 
into the injuried tissue, with consequent tissue swelling. The initial recognition of the 
trigger of inflammation is induced by macrophages resident in the tissue and by mast 
cells. This induces the production of many mediators of the inflammatory response, 
such as cytokines, chemokines, eicosanoids and vasoctive amines. These molecules 
play a crucial role in triggering the recruitment of leukocytes (mainly neutrophils) to 
the site of inflammation, which they can reach following the transmigration through 
activated endothelial cell (EC) monolayers. Once the site of inflammation is reached, 
neutrophils can be activated either by direct interaction with the specific trigger of 
the inflammatory response (eg, pathogens) or by the cytokines released from cells 
which are resident in the tissue. 
Acute neutrophil-induced inflammation is determined by the release of molecules 
normally residing in their granules, as reactive oxygen species (ROS), cathepsin G, 
proteinase 3 and elastase.
1
 The function of these toxic effectors is to eradicate the 
cause of inflammation.  In physiologic conditions, when acute inflammation is 
successful, the acute phase is followed by a tissue repair response exerted by 
macrophages.
2
 A molecule which is crucial for the resolution of inflammation and 
tissue repair is transforming growth factor-β.2;3 
 12 
If the triggering cause of inflammation can't be eliminated by neutrophils, these 
leukocytes are replaced in the tissue by macrophages. T lymphocytes are also 
recruited in case of infection. If all the inflammatory effectors are not sufficient to 
finalize the inflammatory response, this response switches from acute to chronic. 
Chronic inflammation can be induced by persistent pathogens, external non-
degradable bodies and autoimmune diseases, and can be the cause of chronic 
inflammatory diseases. This last case will be considered in the next paragraph. 
During chronic inflammation, the pool of inflammatory leukocytes is mainly 
constituted by mononuclear phagocytes, T cells and eosinophils.
4
 If chronic 
inflammation does not succeed in restoring tissue homeostasis, granulomas might 
form in the inflamed tissue. The functional effect of granulomas is to protect the 
host, by creating a physical barrier between the intruder and the host.
5
 
1.1.1 Role of inflammation in atherosclerosis 
Atherosclerosis, namely a progressive disease induced by the increased presence of 
lipids and fibrous tissue within large arteries, is now a well recognized inflammatory 
disease, although until almost 10 years ago a central role in triggering this disease 
was attributed exclusively to hyperlipidemia without a strong mechanistic 
explanation. Indeed, hyperlipidemia in the arterial intima is often followed by 
modification (eg. oxidation and glycation) of the internalized lipoprotein particles. 
This leads to a chronic inflammation response which is prolonged and kept active by 
the release of pro-inflammatory cytokines and growth factors in the atherosclerotic 
lesion. They act by amplifying monocyte recruitment and macrophage proliferation, 
and by inducing the migration of smooth muscle cells from the media to the intima of 
the vessel.
6
 
 13 
Monocytes play a crucial role in the initiation of the atherosclerotic lesion. They 
reach the intima of the arterial wall, guided by a chemoattractant gradient, after 
having transmigrated through activated EC (see next paragraph). One of the most 
relevant chemotactic proteins during this phase is monocyte chemoattractant protein-
1 (MCP-1). Once the intima is reached, monocytes differentiate into macrophages. In 
the intima, macrophages can bind modified lipoproteins through their scavenger 
receptors and then phagocyte them, therefore becoming foam cells. These cells 
contribute to keep an elevated inflammation state within the plaque, by releasing 
ROS. They also produce matrix metalloproteinases (MMP), that can degrade the 
extracellular matrix and lead to plaque rupture. T-lymphocytes and mast cells are 
also important players in the pathogenesis of atherosclerosis. These cells migrate to 
the arterial intima following a chemotactic gradient. Following their activation, they 
can produce pro-inflammatory cytokines, MMP and the procoagulant molecule tissue 
factor (TF).
8
 
Angiogenesis, namely formation of new blood vessels, plays a role in atherosclerosis 
development by supplying oxygen and nutrients to the growing plaque. A direct 
association has been shown between content of microvessel developing from the 
adventitia to the plaque, and atherosclerotic progression and vulnerability.
7
 
Plaque rupture triggers the onset of blood coagulation, involving the circulating 
platelets and the TF expressed within the plaque. Platelets activation is induced by 
the binding of platelets to collagen and by other pro-coagulant molecules such as von 
Willebrand factor (VWF), a protein released into the blood stream by the damaged 
endothelium. Platelet activation leads to thrombus formation, which can result in 
acute myocardial infarction if the thrombus irreversibly occludes the vessel.
8
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1.2 Role of the endothelium during inflammation  
EC form the inner lining of blood vessels and represent a physical barrier between 
tissues and blood. However, the endothelium is not just an inert membrane which 
maintains the permeability of the vessel wall, but an organ which dynamically 
regulates immunologic, synthetic, metabolic and secretory functions.
9
 
In non-inflamed tissues, resting EC promote the preservation of vascular 
homeostasis. This is exerted non only by regulating blood flow and maintaining its 
fluidity, but also by inhibiting interaction between the endothelium and circulating 
leukocytes, and by regulating the permeability of the endothelial wall.
4
 In resting EC, 
the expression of adhesion molecules such as E-selectin, vascular cell-adhesion 
molecule (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and of pro-
inflammatory chemokines such as interleukin 8 (IL-8) is low. This does not promote 
the adhesion of leukocytes to the endothelium.
10
 This repression is released during 
inflammation, when these molecules are upregulated by EC. 
As mentioned in paragraph 1.1, one of the first events triggering inflammation is EC 
activation, a process in which resting EC acquire new capacities. Up to now, 2 types 
of EC activation have been described. Type I, determined by rapid cell responses 
independent of new gene expression, and type II, which is dependent on newly 
expressed genes and is therefore a slower process.
4
  
Type I EC activation is triggered by the binding of chemokines to G protein-coupled 
receptors (GPCR). Signaling through these receptors lasts for 10 to 20 minutes, since 
these receptors become desensitized after prolonged stimulation.
10
 This type of 
activation leads to increased Ca
2+ 
levels, which induce actin remodelling through 
calmodulin- and RHO-dependent pathways. The functional effect of the activation of 
these signaling pathways is the opening of gaps at tight and adherens junction sites 
 15 
between adjacent cells, mediated by the phosphorylated form of myosin-light-chain 
(MLC). The consequence of this is the leakage of plasma from the blood into the 
inflamed tissue, which constitutes a survival and migrational environment for 
neutrophils invading the tissue.
11
  
As opposed to type I, type II EC activation is more prolonged and sustained, and it 
lasts for hours. The most characterized stimuli which determine type II EC activation 
are IL-1 and TNF-α. They act on specific receptors that trigger transcription factors 
such as NF-kB and AP-1, which drive the expression of adhesion molecules (eg 
ICAM-1, VCAM-1 and E-selectin) or chemokines (such as IL-8). The functional 
consequence of this is an increased leukocyte adhesion to EC. As well as type I, type 
II EC activation induces plasma leakage into the tissue, mediated by cytoskeletal 
rearrangements.
4
 
1.3 Leukocyte adhesion to the endothelium: molecules and 
mechanisms involved 
1.3.1 The leukocyte adhesion cascade 
Following pro-inflammatory stimuli, leukocytes traffic to the inflamed tissue by 
migrating across the activated endothelium. Adhesion molecules expressed on the 
surface of EC play an active role in the regulation of leukocyte adhesion and 
migration into the tissue. Adhesion molecules also trigger specific signalling 
pathways that promote the transmigration of leukocytes after their interaction with 
EC. Leukocyte infiltration into the tissue is a dynamic and multi-step process which 
involves rolling to the endothelium, attachment to the endothelium (arrest), followed 
by transmigration across the EC monolayer (Chapter 1, Figure 1). 
 16 
Rolling of leukocytes on EC is mainly mediated by the low-affinity receptors 
selectins and by selected integrins.
12
 Proteins of the selectin family that play a role in 
this phase are L-selectin (expressed by leukocytes), P-selectin and L-selectin (both 
expressed by inflamed EC). These molecules induce rolling by creating intermittent 
and dynamic interactions with their ligands, which require flow in order to be 
functional.
10
 Integrins on leukocytes involved in rolling are the α4β1-integrin very 
late antigen-4 (VLA4) and the αLβ2-integrin lymphocyte function-associated antigen 
1 (LFA-1),
13
 by transiently interacting with their ligands on EC, respectively VCAM-
1 and ICAM-1.  
Following activation of integrins and their firm interaction with adhesion molecules 
on EC, leukocyte rolling is arrested. By acting on specific GPCR, leukocyte arrest is 
rapidly triggered by chemokines (see paragraph 1.3.2.2) or other chemoattractants, 
and it is physically mediated by the binding of leukocyte integrins of the β1 and β2 
subfamilies to endothelial immunoglobulin superfamily members, such as ICAM-1 
and VCAM-1.
14;15
 Chemokine gradients on the surface of EC also stimulate 
chemotaxis of the arrested leukocytes.
16
 With relevance to this PhD thesis, LFA-1 
binding to ICAM-1 has been extensively studied. LFA-1 binding avidity is enhanced 
by cytokine stimulation and activation of GPCR on leukocytes. The interaction 
between LFA-1 and ICAM-1 is strictly dependent on different affinity states of the 
former molecule. LFA-1 is a transmembrane heterodimer. Its cytoplasmic tail plays a 
critical role in regulating LFA-1 affinity states by interacting with the cytoskeleton. 
Details about ICAM-1 structural domains and their role in interacting with integrins 
will be discussed in paragraph 1.4.1.  
Following activation by leukocytes and other mediators, EC play an active role in 
directing leukocyte endothelial transmigration. Signaling pathways activated by 
 17 
endothelial adhesion molecules result in the relocalization and functional alteration 
of cell junction proteins, and the induction of contractile forces in EC.
17-19
 By 
binding ICAM-1, the β2 integrin macrophage antigen 1 (MAC1) allows leukocytes to 
cross the EC monolayer through induction of leukocyte membrane protrusions 
directed towards EC junctions (a phenomenon referred as leukocyte crawling).
10
 The 
processes mentioned above contribute to open the endothelial cell junctions, allowing 
the leukocytes to migrate into the inflamed tissue through a paracellular route. For a 
minority of leukocytes, transmigration can also occur through a transcellular route 
within EC, induced by endothelial vesiculo-vacuolar organelles acting as 
intracellular gateways.
20
  
1.3.2 Molecules involved in the induction of leukocyte arrest to the 
endothelium 
On leukocytes, the arrest on EC is induced by receptor-mediated signaling events 
that induce conformational changes and activation of integrins. These signalling 
events, referred to as "inside-out", are mediated by chemokines or chemoatractans.  
By acting on GPCR, these molecules induce an almost instantaneous 
Ca
2+
/calmodulin dependent integrin activation.
21
 Chemokines known so far belong to 
4 different groups (CXC, CC, C, CX3C), classified for the presence or absence of 
aminoacids between the first 2 cysteins. A list of these molecules and their receptors 
is shown in Table 1. Chemokines such as interleukin (IL)-8 participate in inducing 
integrin activation on leukocytes. β1-integrin and β2-integrin subfamilies play a 
major role in the induction of leukocyte arrest, and among these 2 groups the best 
characterized molecules are VLA4 and LFA-1. These two integrins respectively bind 
the adhesion molecules VCAM-1 and ICAM-1 on EC (Chapter 1, Figure 1),
21;22
 
central key players of leukocyte arrest on EC. During leukocyte arrest, integrins also 
 18 
strengthen leukocyte adhesion through "outside-in" signalling events induced by 
their binding to endothelial adhesion molecules.
23
 
Among different cytokines acting on EC receptors to induce the expression of 
adhesion molecules involved in leukocyte arrest, TNF-α is one of the best studied so 
far. Because the interest of the project discussed in this thesis is focused on  the 
prevention of TNF-α-induced inflammation and leukocyte adhesion on EC, the role 
of this molecule  in activating pro-inflammatory pathways will be extensively 
analysed in the next paragraph.  
 
 
 
       
Chapter 1, Figure 1. Leukocyte adhesion cascade. The 3 main steps are indicated: 
rolling, arrest and transmigration. ICAM1, intercellular adhesion molecule 1; LFA1, 
lymphocyte function-associated antigen 1; MADCAM1, mucosal vascular addressin 
cell-adhesion molecule 1; PSGL1, P-selectin glycoprotein ligand 1; VCAM1, 
vascular cell-adhesion molecule 1; VLA4, very late antigen 4 (modified from
10
). 
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1.3.2.1 Tumor necrosis factor-α (TNF-α) 
TNF-α is the founding member of the TNF superfamily of cytokines. It is a 26 
kilodalton (kDa) type II transmembrane protein expressed by macrophages, natural 
killer (NK) cells, B- and T-lymphocytes.
24
 It can be cleaved by metalloproteases of 
the ADAM family, leading to the release of a soluble 17 kDa form.
25
 TNF-α binds to 
TNF receptor (TNFR)-1 and TNFR2, and the soluble form preferentially binds 
TNFR1, the most investigated among the 2 receptors.
26
 While TNFR1 is ubiquitously 
expressed, TNFR2 is only expressed by immune cells and EC.
25
 Both these 2 
receptors are type I transmembrane proteins expressed on the cell surface. However, 
TNFR1 is internalized after prolonged stimulation,
27
 and is mainly localized to the 
Golgi.
28
 
Different pathways and biological functions have been characterized downstream to 
TNF-α stimulation of its receptors. Apoptosis can be induced by caspase-3 
activation. This pathway is triggered by TNFR1 stimulation and the consequent 
recruitment of TNFR-associated death domain (TRADD) protein.
29
 Moreover, 
TNFR1 and TNFR2-mediated recruitment of TNFR-associated factor (TRAF)2 and 
TRAF5 activates the AP-1, p38MAPK and NF-kB pathways, leading to pro-
inflammatory and anti-apoptotic effects.
24
 With relevance to this work, a detailed 
explanation of how TNF-α signals to NF-kB is presented in paragraph 1.5.3.1. 
Vascular endothelium is a major target of TNF-α, and in EC biology TNF-α is 
mainly known for its pro-inflammatory properties. It contributes to induce leukocyte 
adhesion to EC by upregulating expression of adhesion molecules (E-Selectin,
30
 
ICAM-1,
31
  VCAM
32
) and chemokines (IL-8,
33
 MCP-1
34
). TNF-α also regulates cell 
morphological changes that may induce leakage at sites of inflammation.
35
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TNF-α disregulation has been associated with a variety of human syndromes. Among 
these, TNF-α plays a major role in the pathophysiology of inflammatory diseases 
such as rheumatoid arthritis, atherosclerosis, allergic asthma, Chron's disease and 
systemic lupus erythematosus.
24
 This led to the development of therapeutic tools 
aiming to inhibit TNF-α function. Anti-TNF-α antibodies,36 and soluble TNFR237 
have now been approved for treatment of human inflammatory diseases. 
1.3.2.2 Interleukin-8 (IL-8) 
IL-8, a member of the interleukin superfamily, belongs to the CXC family of 
chemokines, and binds the chemokine receptors CXCR1 and CXCR2 (Table 1). IL-8 
is a 11 kDa protein secreted by several cell types, and is mainly known for being an 
inducer of chemotaxis and accumulation of neutrophils in vivo.
38
A role for IL-8 in 
inducing monocyte adhesion to EC in static conditions and under flow has also been 
reported in vitro.
39
 In resting cells, secretion of IL-8 is low, but it can be induced by 
more than 100 fold by pro-inflammatory cytokines such as TNF-α and IL-1.40;41 
Other pro-inflammatory stimuli as bacteria
42
 and viruses
43
 also contribute to up-
regulate IL-8 expression. The IL-8 gene is located on chromosome 4. In basal 
conditions, IL-8 promoter activity is inhibited by the binding of NF-kB repressing 
factor (NRF) and octamer-1 (OCT-1), and by histone deacetylase 1 (HDAC-1)-
mediated histone deacetylation. Following TNF-α and IL-1 induction, CREB-binding 
protein (CBP)/p300-mediated histone hyperacetylation, together with C/EBP 
mediated OCT-1 displacement and binding of phosphorylated AP-1 and NF-kB p65 
to the IL-8 promoter, induce IL-8 promoter activation.
44
    
 
 
 21 
 
 
 
 
Table 1. List of main chemokines and their classificaion. GRO, growth-regulated 
gene product; MGSA, melanoma growthstimulatory activity; IL, interleukin; IP, 
interferon-inducible protein; MIG, monokine-induced by interferon γ; NAP, 
neutrophil-activating protein; PF, platelet factor; SDF, stromal cell-derived factor; 
ELC, EBII-ligand chemokine; MCP, monocyte chemoattractant protein; MIP, 
macrophage inflammatory protein; RANTES, regulated upon activation, normal T 
cell expressed and secreted; and CXCR, CXC receptor (from
16
). 
 
 
 
 
 22 
1.3.2.3 Vascular cell-adhesion molecule-1 (VCAM-1) 
VCAM-1 is a 110 kDa protein, member of the immunoglobulin-like superfamily of 
adhesion molecules. Its structure contains 7 immunoglobulin (Ig) domains (Chapter 
1, Figure 2 A), which are separately encoded by 7 of the 9 exons of the VCAM-1 
gene (Chapter 1, Figure 2 B). VCAM-1 is expressed at very low basal levels on EC 
and on some non vascular cells, as bone marrow stromal cells, some monocyte-
derived cells, epithelial cells and dendritic cells.
45-49
 VCAM-1 plays a crucial role in 
mediating leukocyte adhesion on activated EC, by binding the integrins α4β1 
(VLA4) and α4β7 expressed on circulating monocytes and lymphocytes.45 VCAM-1 
expression is rapidly up-regulated by pro-inflammatory cytokines IL-1β, IL-4 and 
TNF-α, and by lipopolysaccharide (LPS).32;50 VCAM-1 promoter contains functional 
binding sites for the transcription factors NF-kB, GATA, IRF-1, AP-1, and SP1 
(Chapter 1, Figure 2 C), implicated in induction of VCAM-1 gene transcription in 
response to a variety of pro-inflammatory stimuli, including TNF-α, LPS and 
cytokines.
51-54
. 2 functional NF-kB binding sites at positions -73 and -58 (Chapter 1, 
Figure 2 C), are involved in VCAM-1 cytokine mediated transcriptional activation.
55
 
Both of these 2 sites are preferentially bound by NF-kB p50-p65 heterodimers in EC 
stimulated with TNF-α.53 
In human disease, VCAM-1 is highly expressed on EC of vessels overlaying 
atherosclerotic lesions,
56
 where it plays a functional role in the recruitment of 
leukocytes to the area of inflammation.
57;58
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Chapter 1, Figure 2. Structure of VCAM-1 protein, gene and promoter. A, Structure 
of VCAM-1 protein (from 
58
). B, structure of the VCAM-1 gene. Exons are indicared 
by black boxes. Introns and 5' and 3' flanking sequences are indicated by lines. 5' and 
3' untranslated regions (UTR) are indicated by white boxes. SP, signal peptide; TM, 
transmembrane region; CYTO, cytoplasmic domain; UT, untranslated region. 
Numbers indicate the 7 Ig domains. C, schematic representation of VCAM-1 
promoter. Numbers indicate the distance in base pairs (BP) from the transcription 
starting site. Boxes indicate the specific transcription factor binding sites (from 
59
). 
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1.4 Intercellular adhesion molecule-1 (ICAM-1) 
1.4.1 Structure and biological function in EC 
ICAM-1 is a member of the immunoglobulin superfamily of proteins, and in human 
is encoded by a gene which maps on chromosome 19. ICAM-1 is a heavily 
glycosilated transmembrane protein, with a molecular weight ranging between 76 
and 114 kDa, depending on the level of tissue specific glycosilation.
60
 ICAM-1 
protein structure contains a small cytoplasmic tail, a hydrophobic transmembrane 
domain and an extracellular domain (Chapter 1, Figure 3 A). The 5 Ig-like domains 
which form the extracellular region are necessary and sufficient to induce leukocyte 
binding to EC,
61
 and are encoded by 5 of the 7 exons of the ICAM-1 gene.
62
 As 
mentioned above, ICAM-1 plays a key role in inducing leukocyte arrest on EC by 
binding the activated integrins LFA-1 and Mac-1 on leukocytes. The specific integrin 
binding sites for ICAM-1 have been mapped: LFA-1 binds to domain 1, and MAC-1 
to domain 3 (Chapter 1, Figure 3 A).
63;64
 ICAM-1 is not only important to mediate 
leukocyte adhesion to EC. The cytoplasmic domain of ICAM-1 plays a role in 
facilitating the transendothelial migration (TEM) of leukocytes via the transcellular 
route.
61
 It is also required to allow ICAM-1 interactions with cytoskeletal proteins, 
such as F-actin, moesin, ezrin and α-actinin.65-67 These interactions are important to 
control the appropriate localization of ICAM-1 on the cell surface.
68
 Indeed, not only 
ICAM-1 density, but also the distribution of ICAM-1 on the EC membrane plays a 
major role in regulating leukocyte TEM. Following binding to active LFA-1, ring-
shape clustering of ICAM-1 in actin-rich microvilli was shown to form along the 
sides of adherent leukocytes.
69
 Clustering of ICAM-1 following LFA-1 induces both 
leukocyte adhesion to EC and TEM.
70;71
 Moreover, ICAM-1 has been shown to form 
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dimers, which have an increased affinity with LFA-1 compared to monomeric 
ICAM-1. Clustering of ICAM-1 is not only important to induce leukocyte TEM, but 
could also regulate transcellular migration through caveolae mediated internalization 
and transcytosis.
20
 
Novel roles for ICAM-1 in triggering intracellular signalling pathways following its 
engagement have also been described. By interacting with the actin cytoskeleton, 
ICAM-1 triggers the extracellular signal-regulated kinase (Erk) 1/2 signaling.
72
 
Moreover, ICAM-1 cross-linking activates the AP-1 pathway,
73
 enhances the 
production of the chemockines IL-8 and RANTES, and induces VCAM-1 expression 
via a NF-kB independent mechanism. ICAM-1 ligation induces RhoA expression in 
EC.
74
 RhoA plays a role in inducing ICAM-1 expression, suggesting that this 
mechanism could potentiate ICAM-1 expression through a positive feedback loop. 
Finally, ligation of ICAM-1 induces Ca
2+ 
increase, required to mediate leukocyte 
transmigration.
75
 Taken together, the signalling effects induced by ICAM-1 
engagement clearly support and strengthen the previously described pro-
inflammatory effects exerted by this molecule. 
1.4.2 Tissue distribution and expression during inflammation and 
disease states 
In normal tissues detectable constitutive ICAM-1 expression is low and restricted to 
some epithelial and vascular EC and occasionally cells in thymus, tonsils and 
proximal tubules in the kidney. ICAM-1 is also expressed by fibroblasts, dendritic 
cells and peripheral blood leukocytes.
60;76;77
 However, upregulation of ICAM-1 can 
be induced in essentially any cell type by exposure to cytokines such as IL-1,
60
 TNF-
α, interferon (IFN) γ, LPS,30 molecules as thrombin78 and oxidants such as H2O2.
79
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ICAM-1 plays an important role in the initiation and maintenance of many human 
diseases. Its expression is increased and exerts functional roles in different 
autoimmune diseases such as rheumatoid arthritis,
80
 lupus erythematosus,
81
 multiple 
sclerosis,
82
 autoimmune diabetes
83
 and asthma.
84
 ICAM-1 is a key molecule in the 
pathophysiology of atherosclerosis. Expression of ICAM-1 is increased on the 
endothelium overlaying inflamed areas of plaque and has been implicated in the 
pathogenesis of atherosclerosis.
85
 Moreover, in Apolipoprotein E (Apo-E) deficient 
mice with atherosclerosis, ICAM-1 was found increased on endocardium and heart 
microvessels.
86
 Furthermore, in ICAM-1 knock-out mice, high fat diet leads to 
smaller atherosclerotic lesions.
87
 ICAM-1 expression is also frequent on malignant 
melanomas
88
 and renal cell carcinomas.
89
 
1.4.3 Regulation of ICAM-1 gene expression in EC 
ICAM-1 expression is mainly regulated at the transcriptional level,
59;90;91
 and the 
ICAM-1 promoter has been extensively studied. It contains a number of potential 
transcription factor binding sites, some of which contribute to its transactivation and 
regulation (Chapter 1, Figure 3 C, Chapter 1, Figure 4). The mechanisms regulating 
basal and induced transcriptional regulation of ICAM-1 will be discussed in the next 
paragraphs. 
1.4.3.1 Basal regulation 
As discussed above (paragraph 1.4.2), ICAM-1 expression levels in many different 
cell types are low in resting conditions, although still detectable. Because of the 
important role played by increased expression of ICAM-1 in inflammation, ICAM-1 
transcriptional regulation in unstimulated cells has not been extensively investigated 
yet. Deletion mutants analysis identified the presence of one silencing and three 
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enhancing regions on the ICAM-1 promoter contributing to its basal regulation. The 
enhancer region upstream to bp -1352 from the transcription start site was found to 
be active in a variety of cell types. However, the active silencer region between  bp -
339 and -290 is absent from many cells types expressing low levels of ICAM-1.
92
 2 
TATA boxes have been identified within the ICAM-1 promoter. The proximal one, 
located 70bp downstream to the translation start site, has been found to be essential 
to regulate ICAM-1 basal promoter activity.
91;92
. An ETS site located at position -158 
from the translational start site has been shown to be functionally bound by the ETS 
transcription factor ERM, and to be necessary to mediate basal ICAM-1 transcription 
in rabbit kidney carcinoma (RK13) cells  and human choriocarcinoma (JEG-3) 
cells.
93
 Finally, mutation analysis identified regulatory elements which are required 
for basal ICAM-1 transcription at position -115, -60 and -40 from the ICAM-1 
transcription start site (Chapter 1, Figure 4).
94
 The transcriptional regulation of basal 
ICAM-1 is currently the focus of another project currently ongoing in our laboratory. 
1.4.3.2 Transcriptional regulation by TNF-α 
As already mentioned, the pro-inflammatory cytokine TNF-α is an inducer of ICAM-
1 transcription.
30
 Deletion mutant analysis of the 5' region upstream from the 
transcription start site of the human ICAM-1 gene has identified crucial regulatory 
elements within the first 1.3 kb.
91;95;96
 Among the binding sites for transcription 
factors known to be induced by TNF-α, sites for AP-1 and NF-kB were identified in 
this region (Chapter 1, Figure 3 C, Chapter 1, Figure 4), and TNF-α stimulation has 
been shown to induce NF-kB specific transactivation of the ICAM-1 promoter.
95
 
Moreover, Zhou et al. have shown that TNF-α induction of ICAM-1 in EC is mainly 
mediated by TNFR1 and occurs through the NF-kB pathway, but not the ERK, 
p38MAPK or JNK kinase pathways.
97
 However, the NF-kB specificity of the ICAM-
 28 
1 induction by TNF-α is controversial, since others have shown a partial role for 
p38MAPK in enhancing its induction.
98
 The proximal NF-kB binding site situated at 
position -228 from the ATG is essential for the TNF-α induction of ICAM-1, since 
its deletion completely abolishes the TNF-α induction of ICAM-1 promoter.96 
Interestingly, this site includes a putative ETS binding site, which has been identified 
by bioinformatic analysis (performed by Dryden N, unpublished data) (Chapter 1, 
Figure 4). The functional consequence of this might be that NF-kB and ETS 
transcription factors co-operate or compete to bind this promoter region. If this is 
true, these proteins might act as fine regulators of ICAM-1 transcription. However, 
the potential co-operation or competition between transcription factors of the ETS 
and NF-kB families on these 2 sites has not been yet investigated. The NF-kB 
subunits which were shown to bind this site following TNF-α stimulation are p65 
homodimers, p50/p65 and p65/c-Rel heterodimers,
96;99
 and p65/65 dimers.
99
 Studies 
in 293A cells showed that p65 is the main NF-kB subunit bound to this site,
100
 and 
that p50 only weakly binds this region.
99
 In HUVEC, p65 is the only NF-kB subunit 
shown to transactivate this region, whereas p50 strongly represses ICAM-1 promoter 
transcription.
96
 An upstream NF-kB binding site has also been mapped on the ICAM-
1 promoter (Chapter 1, Figure 4), but this site does not bind NF-kB and is not 
responsive to TNF-α stimulation.91;95;99 This binding site includes a putative ETS 
binding site, whose sequence is identical to the ETS sequence present on the 
proximal NF-kB binding site. However, this site was not recognized by bioinformatic 
analysis.  
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1.4.3.3 Regulation by other factors 
Reactive oxygen species (ROS) play an important role in the ICAM-1 transcriptional 
induction in EC, either intracellularly or extracellularly via receptor-mediated 
signalling. H202 stimulation induces ICAM-1 expression through the activation of the 
AP-1 pathway and the induction of an AP-1/ETS region on the ICAM-1 promoter, 
respectively at position -940 and -865 from the translation start site
95
 (Chapter 1, 
Figure 3 C; Chapter 1, Figure 4). Intracellular ROS levels can be increased by 
different stimuli implicated in ICAM-1 transcriptional induction, such as shear 
stress,
101
 angiotensin II,
102
 LPS, high glucose levels and cytokines.
103
 Nicotinamide 
adenine dinucleotide phosphate-oxidase (NADPH) is one of the best characterized 
sources or ROS in EC, and has been implicated in the ICAM-1 induction by 
triggering the NF-kB pathway. Thrombin-mediated induction has also been shown to 
induce ICAM-1 transcription through NF-kB, following the upstream activation of 
protein kinase (PK) Cδ104 and phosphoinositide 3-kinase (PI3K).105 Thrombin, as 
well as other stimuli such as LPS nicotine, bile acids and respiratory syncytial virus 
has been shown to induce transcriptional activation of ICAM-1 by triggering the 
MAP kinases, NF-kB and AP-1 pathways.
98;106
 However, the involvement of some 
MAP kinase members in the ICAM-1 upregulation is controversial, and is not in 
agreement with other studies.
107;108
 Finally, proteins belonging to the Rho family of 
small GTPases have also been shown to induce ICAM-1 transcription, mainly 
through cytoskeletal adaptor molecules that induce NF-kB mediated signaling, in 
cells stimulated with  TNF-α  and thrombin.109  
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Chapter 1, Figure 3. Structure of ICAM-1 protein, gene and promoter. A, Functional 
structure of the ICAM-1 protein. S-S: disulphide bonds; D1-5, extracellular domains; 
TM, transmembrane domain; C, cytoplasmic doman. N, N-terminal domain; C, C-
terminal domain. Numbers indicate the amino acid position of the N-terminal 
domains. Binding sites for the LFA-1 and Mac-1 integrins are indicated. B, structure 
of the ICAM-1 gene. Exons are indicared by black boxes. Introns and 5' and 3' 
flanking sequences are indicated by lines. 5' and 3' UTRs are indicated by white 
boxes. SP, signal peptide; TM, transmembrane region; CYTO, cytoplasmic domain; 
UT, untranslated region. Numbers indicate the 5 Ig-like domains (from 
59
). C, 
structure of the ICAM-1 promoter. Black boxes indicate the specific transcription 
factor binding sites. Their distance in bp from the ATG translation start site sequence 
(arrow) is shown (modified from
78
). 
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Chapter 1, Figure 4. Human ICAM-1 promoter. Sequence and binding sites for 
transcription factors involved in ICAM-1 regulation 1.3 kb ustream to the 
transcription binding site (with courtesy of N. Dryden). The following transcription 
factor binding sites are shown: ETS binding sites identified by Matinspector 
bioinformatic analysis (boxed); AP-1 (green boxes) and ETS (yellow boxes) binding 
sites responsive to H202 stimulation; functional cytokine-responsive NF-kB binding 
site (turquoise box) flanking an ETS site (orange box); NF-kB binding site (blue box) 
including a putative, ETS site (shaded orange box, not identified by bioinformatic 
analysis);
99
 ETS sites (red boxes) and functional ETS site required to either promote 
(dashed line)
93
 or repress (emerald box)
94
 basal ICAM-1 transcription. Underlined 
sequence, proximal TATA box; arrow, transcription start site; ATG (bold sequence), 
translation start site. 
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1.5 Nuclear factor kappa B (NF-kB)  
1.5.1 Members of the NF-kB family 
NF-kB is a family of transcription factors which includes 5 members: p50, p52, p65 
(also known as Rel-A), c-Rel and RelB (Chapter 1, Figure 5). These proteins share 
an N-terminal Rel homology domain (RHD), whose function is to mediate homo- 
and heterodimerization (through its N-terminal sequence) and DNA binding (through 
its C-terminal hydrophobic residues).
110
 In human cells, the p50/p65 heterodimer is 
the most abundant NF-kB isoform,
111
 and because of its functional relevance, it is 
also the best studied and characterized. Proteins of the NF-kB family of transcription 
factors bind the consensus promoter DNA sequence 5'-GGGRNNYYCC-3' on target 
genes, where R indicates purine, N indicates any nucleotide, and Y indicates 
pyrimidine. kB-like sequences (5'-HGGARNYYCC-3', where H indicates A, C or T, 
R indicates purine, N indicates any nucleotide, and Y indicates pyrimidine) are also 
targets of NF-kB.
112
 The only NF-kB isoforms that specifically induce gene 
transcription are p65 and c-Rel. This is mediated by their C-terminal transcription 
activation domain (TAD), which is absent from the other members of the family. In 
their inactive state, NF-kB dimers are kept in the cytoplasm by NF-kB inhibitors 
(IkBs, discussed below in paragraph 1.5.3.1), which bind their RHD.
113
 Following 
stimuli-induced degradation of IkBs, NF-kB isoforms are translocated into the 
nucleus, where they recruit coactivators and corepressors and exert their 
transcriptional regulation. Moreover, both RHD and TAD domains are affected by 
post-translational modifications, which finely modulate NF-kB transcriptional 
activity (see below, paragraph 1.5.3.2). 
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1.5.2 Role of NF-kB in inflammation 
NF-kB is one of the most important pathways leading to inflammatory response and 
inflammation-mediated diseases. It was discovered by David Baltimore in 
1986,
114
and since then it has been the target of assiduous research in fields 
encompassing not only inflammation, but also cell survival and apoptosis.   
Members of the NF-kB family are mainly known for their ability to regulate 
inducible gene expression, which can be exerted by their ability in binding DNA and 
regulating gene transcription. The specific mechanisms regulating this complex 
pathway will be analysed in the next paragraphs, whereas here the role of NF-kB in 
regulating inflammation will be discussed.  
NF-kB is quickly activated by a variety of stimuli, including cytokines such as TNF-
α and IL-1, stress inducer molecules, viruses, bacteria and yeast products, UV light, 
genotoxic and oxidative stress, and DNA damage.
115
 Each extracelluar molecule 
inducing NF-kB signaling act by binding its specific cell surface receptor, which 
therefore triggers and initiates the pathway. Among the best characterized pathways 
mediating NF-kB activation are those triggered by TNFR, Toll-like receptors (TLR), 
IL-1 receptors (IL-1R), T-cell receptors (TCR) and B-cell receptors (BCR).
116
 This 
leads to the activation of NF-kB proteins (see below, paragraph 1.5.3.1), and to the 
subsequent transcriptional regulation of target genes, some of which play a crucial 
role in inflammation. These include adhesion molecules (ICAM-1, VCAM-1, E-
Selectin, P-Selectin), cytokines (TNF-α, IFN-γ, IL-1 and IL-6), chemokines (IL-8 
and MCP-1) and MMP.
117-120
 It is now clear that NF-kB is a major actor in the 
pathogenesis and maintenance of inflammatory diseases. NF-kB is activated in the 
inflamed synovial tissue of patients affected by rheumatoid arthritis;
121
 it contributes 
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to the progression of asthma,
122
 and plays a role in the pathogenesis of cachexia.
123
 
NF-kB activation has been detected in human atherosclerotic plaques,
117
 and 
increased expression of different NF-kB members was found on EC overlaying 
regions in the aorta that are more prone to develop atherosclerotic lesions.
124
 During 
the first stages of atherosclerosic lesion progression, EC play a critical role in 
inducing leukocyte transmigration into the inflamed area, mainly by increasing the 
expression levels of adhesion molecules and chemokines. This is induced by 
different stimuli known to exert functional effects by activating NF-kB, including 
pro-inflammatory cytokines (discussed above), low-density lipoproteins (LDL),
125
 
advanced glycation endproducts,
126
 viruses
127
 and bacteria.
128
 In later stages of the 
atherosclerosis lesion progression, the NF-kB target genes macrophage colony-
stimulating factor (M-CSF) and MMP-9 play a role in inducing monocyte 
differentiation and migration into tissues.
117;129;130
 
Intriguingly, NF-kB is not only a critical positive regulator of inflammation. It also 
plays a role in inducing cell survival by positively regulating protective genes such as 
Bcl-2 family members and A20.
131
 Moreover, NF-kB is also activated by oncogenes 
such as Ras.
132
  
NF-kB is considered a therapeutic target. Anti-inflammatory compounds widely used 
in clinics, such as glucocorticoids and aspirin, and immunosuppressive drugs such as 
cyclosporine A, are known to suppress NF-kB activity.
133;134
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1.5.3 Proteins belonging to the NF-kB signaling pathway 
1.5.3.1 Members of the I-kB family 
Members of the IkB family play a key role in the regulation of inflammation. This 
family of proteins includes the typical IkB proteins IkBα, IkBβ, IkBε, and the 
atypical IkB proteins IkBγ, IkBδ and Bcl-3 (Chapter 1, Figure 5). They are all 
characterized by the presence of ankyrin repeat domains in their aminoacidic 
sequence. The biological role of the typical IkB proteins is to keep the NF-kB dimers 
in the cytosol in an inactive state (see above). The founding and best characterized 
member of this group is IkBα. While bound to p50/p65 dimers, IkBα masks the 
nuclear localization sequence (NLS) of p65,
135
 preventing the nuclear translocation 
of the complex. The key event which allows the NF-kB dimers to translocate into the 
nucleus and promote their transcriptional activity is the IkBα phosphorylation on 
Ser32 and Ser36, mediated by the inhibitor of kB kinase (IKK) complex. These 
events are followed by IkBα polyubiquitination at Lys48 mediated by the proteins 
βTrCP containing SCF ubiquitin ligase complexes (SCFβTrCP) and by E2 UbcH5,136 
which lead to proteosome-mediated IkBα degradation and NF-kB nuclear 
translocation. TNF-α is a well known inducer of IkBα degradation. IkBα is degraded 
after 15 to 30 minutes of TNF-α stimulation, and then resynthesized to reach basal 
levels. IkBα recovery reaches 50% of basal levels after 4 hours in EC,97 while in 
other cells this is complete in just 1 hour.
137
 IkBα synthesis is under the 
transcriptional control of p65, creating a negative feedback loop: newly synthesized 
IkBα binds NF-kB in the nucleus and directs the complex back to the cytoplasm, 
where NF-kB is inactive.
44;138;139
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1.5.3.2 Members of the IKK family 
In order to respond to pro-inflammatory stimuli and to activate NF-kB, IkB proteins 
require a fine regulation by upstream kinases. This process is mediated by members 
of the IKK family. These are IKKα, IKKβ and IKKγ (also called NF-kB essential 
modulator (NEMO)) (Chapter 1, Figure 5). These proteins are localized in the 
cytosol in an heteromeric complex. Leucine zipper domain of IKKα and IKKβ 
induces their dimerization, and both these two proteins bind IKKγ through the C-
terminal NEMO-binding domain (NBD).
140
 Their functional role is to phosphorylate 
IkBs (see above). IKKβ can independently induce the phosphorylation of IkBα and 
IkBβ that leads to their degradation (canonical NF-kB pathway), while the 
noncanonical NF-kB pathway, resulting in p100 phosphorylation and processing to 
p52, is selectively mediated by IKKα. In order to be enzimatically active, the IKK 
complex has to be phosphorylated. IKKα is phosphorylated on Ser176 and180, while 
IKKβ is phosphorylated at Ser177 ad Ser181. IKK phosphorylation can be either 
mediated by transautophosphorylation events, or by upstream IKK kinases (IKK-K) 
activity.
141
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Chapter 1, Figure 5. Members of the human NF-kB, IkB and IKK families. Numbers 
on the right indicate the aminoacidic length of each protein. The most relevant 
posttranslational modifications and the respective residues are indicated. P, 
phosphorylation; Ac, acetylation; Ub, ubiquitination. Posttranslational modifications 
highlighted in red lead to proteasomal degradation. RHD, Rel homology domain; 
TAD, transactivation domain; LZ, leucine zipper domain; GRR, glycine-rich region; 
HLH, helix-loop-helix domain; Z, zinc finger domain; CC1/2, coiled-coil domains; 
NBD, NEMO-binding domain; MOD/UBD, minimal oligomerization domain and 
ubiquitin-binding domain; DD, death domain (from
142
). 
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1.5.4 Regulation of NF-kB activity 
1.5.4.1 IkB-dependent TNF-α-induced NF-kB activation 
NF-kB signaling downstream of TNFR1 is one of the most studied and characterized 
so far, although some of the molecular regulatory mechanisms still have to be 
discovered. As mentioned before, TNF-α induces the IKK-mediated phosphorylation 
and degradation of IkBα. This allows the NF-kB homo- and hetero-dimers to 
translocate into the nucleus, where they can exert their transcriptional activity 
(Chapter 1, Figure 6). In this paragraph the components that signal from TNFR1 to 
IKKs will be discussed.  
After the TNF-α-induced association of TNFR1 with TRADD, TRADD recruits 
proteins of the TNF receptor associated factor (TRAF) family (see paragraph 
1.3.2.1). TRAF proteins appear to be functional in all the biological systems where 
NF-kB activity is induced.  7 TRAF proteins have been identified so far. Following 
TNF-α binding to TNFR1, TRAF2 together with TRAF5 are recruited to the receptor 
and are required to induce the downstream signaling cascade.
143
 
Receptor-interacting proteins (RIP) belong to a family of 7 serine/threonine kinases 
that signal from the upstream TRAF proteins to the downstream IKKs in a number of 
NF-kB related pathways, such as the Toll/IL-1R and TNFR ones.
144
 RIP1 interacts 
with IKKγ and is essential for IKK activation.145 Rip1 kinase activity is not essential 
to mediate TNF-α-induced IKK activation.146 This suggests that RIP1 might either 
activate a downstream and yet unknown kinase, or that its binding with IKKγ could 
induce IKK autophosphorylation.
147
 Moreover, following TNF-α stimulation and 
TRAF2 binding to RIP1, the latter becomes ubiquitinated, and this process is 
required to activate the downstream signaling pathway.
148
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TGFβ-activated kinase-1 (TAK1) is essential to mediate the TNFR1-induced NF-kB 
signalling.
149
 TAK1 acts downstream of RIP and TRAF, and could activate the IKK 
complex either directly as an IKK-K, or by inducing the activity of a downstream 
kinase, as MAP/ERK kinase kinase 3 (MEKK3)
148;150
  
Finally, in order for the TNF-α-induced signaling to activate NF-kB, other proteins 
act as scaffolds to localize IkBα and the IKK complex in functionally active sites. 
Heat shock protein 90 (Hsp90) and Cdc37 shuttle IKKs from the cytoplasm to the 
cell membrane, while Glu-Leu-Lys-Ser (ELKS) connects the IKK complex to the 
downstream IkBα.  
The mechanisms described here highlight the complexity of the NF-kB signaling 
regulation, and demonstrate how the coordinated function of different molecules 
needs to be finely tuned in a specific special and temporal way. In this signaling 
pathway, a further level of complexity is conferred by the post-translational 
modifications affecting NF-kB transcription. These modifications will be analysed in 
the next paragraph. 
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Chapter 1, Figure 6. TNF-α mediated induction of the NF-kB pathway. Following 
TNF-α binding to TNFR1, the adaptor proteins TRADD, RIP and TRAF are 
recruited to the cell membrane. This complex interacts with the IKK proteins and 
activates them, eventually via TAK1. Hsp90 and Cdc37 connect the IKK complex to 
the cell membrane, while ELKS scaffolds IkBα to the IKKs. Upon IKK-mediated 
phosphorylation of IkBα, IkBα gets poly-ubiquitinated and degraded. This leads to 
the translocation of the NF-kB dimers p50/p65 into the nucleus, where 
phosphorylated and active p65 can transactivate specific target genes on kB sites. 
Newly synthesized IkBα binds NF-kB in the nucleus and redirects it back to the 
cytoplasm, creating a negative-feedback loop (modified from
151
).  
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1.5.4.2 IkB-independent NF-kB activation: post-translational 
modifications of p65 
Members of the IKK, IkB and NF-kB families of proteins are affected by a number 
of post-translational modifications, which finely modulate NF-kB activity through 
mechanisms that are often independent from the canonical pathways relying on the 
degradation of IkBα. In particular, post-translational modifications of p65 are crucial 
to regulate the transcriptional regulation of target genes. Different residues on p65 
have been mapped as targets of modifications such as phosphorylation, acetylation, 
oxidation and proline isomerisation (Chapter 1, Figure 7). p65 can be acetylated by 
the 2 transcriptional coactivators CBP and p300 at Lys-218, Lys-221 and Lys-310. 
These modifications lead to a decreased affinity between p65 and new synthesized 
IkBα, to an increased DNA binding of p65, and to an increased p65 transactivation 
potential.
152
 Opposite effect is exerted by p65 acetylation at Lys-122 and Lys-123, 
leading to a repression of p65 transcriptional potential. p65 oxidation at Cys 38 also 
leads to functional inhibition of p65 activity, while its proline isomerisation at Pro 
255 induces its stabilization, nuclear translocation and transcriptional activity.
153
 
Numerous studies have described the effects of p65 phosphorylation-induced by a 
variety stimuli. These events are mediated by specific kinases (Chapter 1, Figure 7 
B) and can occur in the cytoplasm or in the nucleus. p65 transactivation potential is 
particularly affected by phosphorylation of its TAD domains, but modifications on 
the RHD and other domains also have functional relevance. Indeed, Ser 276 
phosphorylation, which positively regulates p65 transcriptional potential in response 
to TNF-α , can be induced by a catalytic subunit of PKA (PKAc) and by the 
mitogen- and stress-activated protein kinase-1 (MSK1).
154;155
 Adopting a similar 
mechanism, protein kinase C (PKC)-δ phosphorylates p65 at Ser 311, enhancing its 
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transcriptional activity in TNF-α stimulated cells.156 p65 has also been shown to be 
phosphorylated at Ser-276 by pro-inflammatory stimuli. The functional consequence 
of this is an increased p65 binding to DNA, and a higher affinity of p65 for the 
coactivators CBP/p300. Interestingly, phosphorylation events not always increase 
p65 transcriptional potential. Phosphorylation at Thr 435 and Thr-505 were shown to 
repress p65 trancriptional activity,
157;158
 and Ser-468 phosphorylation by glycogen 
synthase kinase (GSK)-3β, IKKβ and IKKε can both stimulate and repress p65 
transactivation potential.
159-161
 These 3 last modifications affect residues within the 
p65 TAD. Other residues on p65 TAD which can be phosphorylated are Ser 529 and 
Ser 536, both playing a role in inducing p65 transcriptional activity.  
p65 can be phosphorylated at Ser 536 by a variety of kinases, including IKKα, IKKβ, 
IKKε, TRAF family member associated (TANK)-binding kinase 1 (TBK1) and 
serine/threonine kinase ribosomal S6 kinase 1 (RSK1).
159;162-164
 P65 is known to be 
phosphorylated at Ser 536 in the cytoplasm,
162
 although one study has shown that the 
phosphorylation of Ser 536 specifically induced by RSK1 occurs in the nucleus.
164
 
Molecules that have been reported to induce p65 Ser 536 phosphorylation include 
TNF-α, lymphotoxin-β,165 LPS,166 and Gram negative bacteria.167 Using phospho-
inactive mutant constructs, the role of this posttranslational modification in the 
induction of NF-kB transcriptional activity has been described.
165-167
 This effect has 
been suggested to be mediated by an increased association between p65 and 
CBP/P300.
168
 p65 Ser 536 phosphorylation has also been shown to induce IL-8 
promoter activity
159
 and has been proposed to play a role in the induction of ICAM-1 
expression.
167
 Finally, this modification has been shown to reduce IkBα levels, 
suggesting that p65 phosphorylation at this site could repress the IkBα-mediated NF-
kB negative feedback loop.
163
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Chapter 1, Figure 7. Post-translational modifications regulating p65 activity. A, P65 
residues and modifications are shown. B, the effects of each modification and some 
of the enzymes involved are listed (from 
136
). C, Cysteine oxidation; Ac, acetylation; 
Pr, proline isomerisation; TA, transactivation domain. Numbers correspond to p65 
aminoacidic sequence. 
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1.6 The ETS family of transcription factors 
1.6.1 Structure of the ETS transcription factors 
E26 transformation specific (ETS)-1 is the founding member of the ETS family of 
transcription factors, from which this family derived its name. ETS transcription 
factors share a conserved ETS domain of ≈85 amino acids, which contains 3 α-
helixes and 4 β-sheets (Chapter 1, Figure 8). The ETS domain mediates binding of 
the ETS proteins to the consensus sequence GGA(A/T) on DNA, although the 
affinity of this binding is also influenced by adjacent sequences.
169
 The integrity of 
the ETS domain is critical for ETS proteins to exert their functional DNA binding, 
since the alteration of a single amino acid within the DNA-recognition helix of this 
domain can alter the specificity of ETS proteins to bind DNA.
170
 Acting via the ETS 
domain, ETS proteins have been estimated to bind between 5 and 15% of gene 
promoters.
171
 Moreover, the ETS proteins can be divided into subfamilies based on 
the homology of their ETS domain.
172
 Another conserved domain shared by 11 
members of the ETS family is the pointed (PNT) domain, consisting in 5 α-helixes 
(Chapter 1, Figure 8). Other domains identified in the ETS family of transcription 
factors are the TAD, the inhibitory domain (ID) and the repressor domain (RD) 
(Chapter 1, Figure 10). 
1.6.2 Biological functions of the ETS transcription factors  
ETS transcription factors are important in the regulation of many biological 
mechanisms such as cell growth, differentiation and survival, and in processes that 
include haematopoiesis, angiogenesis, wound healing, cancer and inflammation.
173
 
So far, 27 members of the ETS family have been identified in mammalian cells, and 
two-thirds are expressed ubiquitously in the adult tissue.
172
 Interestingly, almost all 
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the endothelial promoters characterized so far contain multiple ETS binding sites, 
suggesting that these proteins play a crucial role in regulating EC expression.
174
 A 
domain of particular interest is the PNT domain, which has been shown to mediate 
transcriptional repression,
175
 homo-oligomerization
176
 and heterodimerization.
177
  
Many ETS factors have been shown to act as activators of gene expression. 
However, some of them, such as Yan, ETS-2, Erf, Net, Tel and Erg, can act as 
repressors.
178
 It is becoming evident that some ETS factors can exert both activator 
and repressor properties. Erg can not only transactivate target genes such as Ve-
Cadherin
179
 and ICAM-2,
180
 but can also repress the expression of ICAM-1
181
 and 
IL-8
182
 (see paragraphs 3.2.3.1 and 3.2.4.1), and repress the ETS-2 mediated 
induction of the MMP-3 promoter.
183
 Moreover, the biological activity of Net can 
switch from being repressive to become activating, when Net is activated by Ras.
184
 
Because of the different and sometimes opposite effects exerted by these molecules, 
the complexity of the functional regulation of the ETS family of transcription factors 
is of particular interest. 
1.6.3 Exprerssion of the ETS transcription factors in EC 
Among the ETS family of transcription factors, 19 members have been shown to be 
expressed in human EC, and the detectable expression level of 15 ETS factors has 
been shown to be >10 mRNA copies per cell,
171
 suggesting that they might play 
functional roles in EC biology. In adult and differentiated EC, the ETS protein most 
highly expressed is Ets related gene (Erg), with an expression level reported in one 
study as 243 mRNA copies per cell.
171
 This is of particular interest for the study 
presented in this thesis, since this molecule exerts an important role in the 
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maintainance of EC homeostasis and can be downregulated by pro-inflammatory 
stimuli (see paragraph 1.7).  
1.6.4 Role for ETS transcription factors in inflammation 
In the last decade, evidence for cross-talks between function and/or regulation of 
some ETS transcription factors and the modulation of vascular inflammation has 
emerged. The majority of ETS transcription factors which play a role in 
inflammation are regulated by pro-inflammatory stimuli and exert pro-inflammatory 
properties. These molecules will be described in this paragraph. ETS-1, founding 
member of the ETS family of transcription factors and probably the best 
characterized ETS factor so far, is a clear regulator of vascular inflammation. Its 
expression is induced in EC by the pro-inflammatory stimuli angiotensin (Ang)-2, 
thrombin, IL-1β, ROS and TNF-α.169;185;186 The pro-inflammatory genes MCP-1 and 
VCAM-1 are targets of ETS-1, and ETS-1 levels are increased in vascular smooth 
muscle cells (VSMC) of some atherosclerotic lesions.
169
 Other studies highlight the 
importance of this protein as a functional effector of pro-inflammatory signalling: 
Ang-2-induced vascular inflammation is reduced in ETS-1 deficient mice,
185
 and 
disruption of the ETS-1 gene has been related with decreased numbers of NK T cells 
and functional responses exerted by Th1 cells.
187
 
Conversely, ESE-1, another ETS factor involved in the regulation of inflammation,  
is only expressed in epithelial cells in resting conditions. However, its expression is 
induced in EC and VSMC by pro-inflammatory stimuli such as IL-1β and TNF-α in 
vitro, and in an inflammation model of endotoxemia in vivo.
174
 Among the genes 
regulated by ESE-1 are NO synthase 2 (NOS2) and cyclooxygenase (COX)-2.
174
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Moreover, this transcription factor can regulate the expression of Ang-1-induced by 
TNF-α.188 
Elk-3 is a transcriptional repressor of the anti-inflammatory molecule heme 
oxigenase-1 (HO-1), and can be downregulated by endotoxin.
189
 Similarly, Elk-3 can 
also exert its transcriptional repression on NOS2.
190
 
Lastly, depletion of the ETS transcription factor MEF in mice determines a decrease 
of NK cells which also results in a reduction of these cells' function. MEF can 
positively induce the pro-inflammatory genes perforin, IL-8 and IFN-γ, indicating a 
role for this protein to regulate immunity and vascular inflammation.
191
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Chapter 1, Figure 8. Structure of the ETS domain and pointed domain of Ets-1. The 
location of helices (H) and β-strands (β) within the structures of the pointed domain 
(blue) and ETS domain (red) of Ets-1 are shown (from
173
). 
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Chapter 1, Figure 9. Phylogenetic tree of ETS family members. Phylogenetic tree 
showing the evolutionary relationship between different ETS factor family members, 
based on the relative conservation of the Ets domain, linking members with closely 
homologous amino acid sequences. ETS genes expressed in HUVEC with mRNA 
levels above 1 copy per cell are highlighted (from
174
). 
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Chapter 1, Figure 10. Structure of ETS proteins. Boxes identify the structural 
domains of different ETS family members including the Ets domain (Ets); Pointed 
domain (PNT); transactivation domain (TAD); inhibitory domain (ID); A/T hook 
domain (A/T); and repressor domain (RD) (from
169
). 
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1.7 The Erg protein 
1.7.1 Erg expression and isoforms  
Erg is an ETS transcription factor whose expression is constitutive in EC, and 
apparently restricted to EC,
180
 megakariocytes,
192
 chondrocytes,
193
 and premature B 
and T lymphocytes.
194
 
Up to nine splice variants of Erg, originated from a gene encoding 17 exons,  have 
been identified: Erg-1, Erg-2, p55 Erg (Erg-3), p49 Erg (Erg-4), p38 Erg (Erg-5), 
Erg-6, Erg-7, Erg-8, Erg-9 (Chapter 1, Figure 11).
195;196
 Of these variants, the first 5 
encode for proteins that have been shown to be transcriptionally active and to bind 
DNA.
195
 The two major Erg isoforms in ECs are p55 and p38 Erg: this was identified 
by RT-PCR, northern blotting and rapid amplification of 5' cDNA ends (5'-RACE). 
No differences in the transcriptional activity of these 2 isoforms have been identified 
yet. 
1.7.2 Erg structural domains  
The best characterized Erg domain structure comes from a study performed on the 
Erg-2 protein, carried out by analysing the transcriptional and DNA binding activity 
of specific Erg deletion mutants. This molecule consists of a 5'-Erg/ETS 
transcriptional activation (ETA) domain (aa. 148-207), a negative regulatory 
transcriptional activation (NRT) domain (aa 209-283), an ETS DNA binding (EDB) 
domain (aa 283-382) and a carboxy terminal transcriptional activation (CTA) domain 
(aa 415-462) (Chapter 1, Figure 12).
197
 These domains are also present in the two 
endothelial Erg isoforms p55 Erg and p38. As for other ETS proteins, Erg’s EDB is 
necessary and sufficient to mediate Erg binding to DNA. This domain is constituted 
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by a helix-turn/loop-helix structure and by a stretch of basic amino acids. This 
secondary structure is conserved in the 3'-ETS domain regions of the ETS factors c-
ETS-1, ETS-2, Elk-1 and Fli-1.
198
 
The ETA domain plays a major role in transcriptional activation of the Erg protein. 
However, deletion of the amino-terminal region of Erg-2 (including the ETA 
domain) does not abolish transcriptional activation, suggesting the presence of 
another transactivation domain (possibly at the C-terminus). Deletion of the CTA 
domain leads to full transcriptional activity of Erg-2, suggesting that the ETA 
domain can induce transcriptional activation autonomously.
197
 The deletion of the 
NRT domain from full-length Erg-2 shows a higher transcriptional activity. This 
domain contains proline rich sequences, covering 16% of this domain, that may play 
a role in the negative regulation of ERG transcriptional activity.
197
 
Interestingly, Erg can be a target of post-translational modifications. It has been 
shown that Erg-2 is phosphorylated by activation of PKC, mainly on serine residues, 
in human acute myeloid leukemia (KG1) cells. This phosphorylation is stimulated by 
phorbol myristate acetate.
199
 At present, no data are available in the literature 
describing an effect on Erg function due to this modification.  
1.7.3 Erg and its biological function 
In normal conditions, Erg exerts its biological function by regulating hematopoiesis 
and hematopoietic stem cell function, and by maintaining normal numbers of mature 
blood cells. Because in humans Erg maps to chromosome 21 (21q22), the Erg 
triploid gene dosage in Down's syndrome has been proposed to be a possible 
contributor to the megakaryocytic leukemia linked to this syndrome.
192
 Erg is of 
particular interest for its role in the pathogenesis of different cancers. Translocations 
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of the Erg’s ETS domain can be the cause of prostate cancer200 and Ewing's 
sarcoma,
201
 and abnormal Erg expression levels have been linked to prostate 
cancers
200
 and hematopoietic cancers such as myeloid
202
 and T lymphoblatic
203
 
leukemias. Erg also plays important roles in the regulation of a variety of processes 
in the vasculature. These will be discussed in detail in the next paragraphs (1.7.2 and 
1.7.3). 
 
 
 
Chapter 1, Figure 11. Structure of the human ERG gene. A, schematic representation 
of the ERG gene. Exons are indicated by black boxes, and numbered starting from 
the 5' exon. B, structure of alternative transcripts encoded by the ERG gene. Start 
codons are indicated by an asterisk (*) and stop codons are indicated by a hatch (#). 
Open reading frames are shown in black boxes, the 5'UTRs and 3'UTRs in white 
boxes, and the transcribed exons in grey boxes. Red arrows indicate the Erg isoforms 
expressed in ECs (modified from
195
). 
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Chapter 1, Figure 12. Schematic representation of the ERG-2 functional domains. 
ETA, Erg/ETS transcriptional activation domain. NRT, negative regulatory 
transcriptional activation domain. EDB, ETS DNA binding domain. CTA, carboxy 
terminal transcriptional activation domain. 
 
1.7.4 Erg and its role in the endothelium 
Erg has recently emerged as a central actor in regulating different aspects of vascular 
biology. Not surprisingly, this molecule is the most highly expressed in EC, among 
all the members of the ETS family of transcription factors (see paragraph 1.6.3). 
One of the main features exerted by Erg in the endothelium is its major role in the 
induction and regulation of angiogenesis. Data from our lab showed for the first time 
that Erg expression in ECs is important to mediate angiogenesis both in vitro and in 
vivo. This was demonstrated by performing matrigel tube assays in Erg deficient 
HUVEC,
204
 and by injecting a matrigel plug pretreated with Erg siRNA in mice.
179
 A 
functional analysis of Erg in zebrafish further confirmed that Erg is required to 
induce vascular development, possibly via direct regulation of VE-Cadherin.
179
 
Moreover, Erg has been implicated in the transcription of vascular endothelial 
growth factor receptor (VEGFR)-1
205
 and VEGFR-2,
206
 two receptors for VEGF, one 
of the most studied growth factor that induce angiogenesis. This suggests that Erg 
may also play an important role in modulating pro-angiogenic pathways directly. 
To further highlight Erg as a main player in endothelial biology, data from animal 
models suggest that Erg is involved in endothelial differentiation and vascular 
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development,
207
 and that is required for the differentiation of embryonic stem cells 
along the endothelial lineage.
208
 Moreover, Erg has been implicated in driving the 
expression of genes that define the endothelial lineage, such as VWF
204
 and 
endoglin.
209
 In agreement with these findings, Erg over-expression in Xenopus 
embryos results in ectopic differentiation of the endothelium.
174
 It is also clear that 
Erg is necessary to maintain endothelial homeostasis, through the modulation of 
junctional stability and cell survival.
180
 It is required to modulate the constitutive 
endothelial expression of ICAM-2
180
 and VE-Cadherin,
179
 key regulators of 
endothelial intercellular junctions and vessel stability. Finally, data from our 
laboratory indicate that Erg is required in EC to protect the cells from apoptosis. 
Inhibition of Erg expression in HUVEC results in increased cell death, indicating that 
Erg regulates endothelial survival through a mechanism partially driven by VE-
Cadherin.
179
 
All these data clearly point to a positive role for Erg in promoting critical functions 
characteristic of the resting vascular endothelium, and partly helped us to formulate 
the hypothesis that this molecule might also exert protective functions in non 
physiological conditions, such as during inflammation.  
1.7.5 Erg and inflammation 
In the last years, few separate studies suggested that Erg might play a central role not 
only in the regulation of angiogenesis, endothelial homeostasis and survival, but also 
in the modulation of vascular inflammation. Moreover, as it will be discussed below, 
this molecule can also be a target of pro-inflammatory stimuli, indicating that the 
fine regulation of Erg’s expression in EC might be critical during inflammation.  
 56 
1.7.5.1 Erg regulation of inflammation 
The first indication that Erg might play an anti-inflammatory role in EC comes from 
a study carried out by Laumonnier and colleagues. This group showed that Erg 
drives the anti-inflammatory gene eNOS, by transactivating an enhancer sequence 
located 4.9 kb upstream of the transcription start site.
210
 Although no data about Erg 
regulation of eNOS expression levels are available in the literature, this suggest that 
Erg might drive anti-inflammatory pathways. Moreover, Erg is also involved in 
driving the expression of Bcl-2 (Birdsey G. et al., unpublished data), which as well 
as its known anti-apoptotic effects, can have an anti-inflammatory effect in EC via 
inhibition of NF-kB activation.
211
 Additionally, a microarray performed in our lab 
identified for the first time specific pro-inflammatory genes which were up-regulated 
following Erg inhibition in EC (Birdsey G. and Randi A.M., unpublished data). 
Some of these putative targets, such as ICAM-1, VCAM-1 and IL-8, were chosen for 
further investigation in this PhD thesis because of their relevance in vascular 
inflammation. Interestingly, a recent study from Yuan and colleagues not only 
confirmed this, but also uncovered new insights highlighting the potential anti-
inflammatory role of Erg. In this article, Erg was shown as a transcriptional repressor 
of IL-8 and leukocyte adhesion in vitro.  These data were obtained using an siRNA 
approach to inhibit Erg in HUVEC. Although no explanation of the mechanisms 
regulating these two processes are reported, this is the first study indicating a 
potential role for Erg in repressing inflammation.  
1.7.5.2 Erg regulation by pro-inflammatory stimuli 
Erg not only seems to exert its function in repressing vascular inflammation, but it is 
also a target of inflammatory stimuli. Three separate studies have shown that Erg 
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expression is down-regulated under pro-inflammatory conditions. Erg protein is 
down-regulated by TNF-α both in vitro180 and ex vivo in mammary artery endothelial 
cells.
180
 Moreover, Erg is down-regulated in hearts of mice treated with LPS as well 
as in a mouse model of endotoxemia.
182
 Although the pathways by which these 
conditions down-regulate Erg levels have not yet been elucidated, these findings 
suggest that Erg downregulation might play a role in inducing EC activation. 
Interestingly, TNF-α has been shown to down-regulate the expression of eNOS212 
and Bcl-2,
213
 two Erg target genes (see above). Therefore, Erg reduction could be 
partly involved in the TNF-dependent down-regulation of these two constitutive 
genes. 
Taken together, the data reported in this paragraph indicate that Erg might play a 
central role in repressing vascular inflammation. If this is confirmed, once the anti-
inflammatory effects of Erg will be fully uncovered and characterized, this protein 
could become a new therapeutic target for the modulation of inflammation, and 
eventually a new potential approach to treat inflammatory diseases. 
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HYPOTHESIS AND AIMS OF THE PROJECT 
The overall hypothesis of my work, summarized in Chapter 1, Figure 13, is that in 
healthy ECs constitutive Erg represses the expression of anti-inflammatory genes. 
During inflammation, cytokines such as TNF-α increase the expression of pro-
inflammatory genes, such as ICAM-1, VCAM-1 and IL-8. On the other hand, pro-
inflammatory stimuli downregulate Erg levels. I propose that Erg can inhibit pro-
inflammatory pathways, and that its down-regulation is necessary to allow a full-
blown inflammatory response to occur. Therefore, my aim has been to identify a 
potential role for Erg in protecting the resting endothelium from activation, and to 
prove for the first time that Erg has a functional role in preventing inflammation. In 
particular, I have been focusing on the following points: 
• To characterize the ability of Erg to repress the expression of the pro-inflammatory 
molecules ICAM-1, VCAM-1 and IL-8, and to identify the mechanisms leading to 
the Erg repression of ICAM-1. 
• To determine whether Erg has a functional role in repressing leukocyte adhesion in 
vitro and inflammation in vivo. 
• To identify molecular targets and mechanisms within the inflammation pathways 
that are regulated by Erg.  
• To analyze the mechanisms leading to Erg downregulation following TNF-α 
stimulation. 
• To explore the potential link between Erg expression and inflammation in human 
disease. 
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Chapter 1, Figure 13. Erg and inflammation: model. In healthy EC the expression of 
adhesion molecules is low, keeping EC in a resting state. However, following TNF-α 
stimulation their expression increases, the endothelium becomes activated, and Erg 
gets downregulated. Therefore we hypothesize that Erg downregulation by TNF-α 
might be necessary for TNF-α to activate EC, and that by over-expressing Erg in 
TNF-α treated cells the pro- inflammatory consequences induced by TNF-α might be 
rescued. 
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CHAPTER 2: MATERIALS AND METHODS, TOOLS 
GENERATION 
2.1 Materials and methods  
2.1.1 HUVEC isolation  
Umbilical cords were washed twice with 20 ml HBSS and incubated with 0.5mg/ml 
Collagenase-A (Roche) in 20 ml HBSS at 37° C and 5% CO2 for 8 minutes. The cell 
suspension was collected in a 50 ml tube, and centrifuged for 8 minutes at 306 g, 
room temperature. The cell pellet was resuspended in 5 ml complete M199 medium, 
and transferred to a 25 cm
2
 flask (Corning) precoated with 1% gelatin. The following 
day the medium was changed, and cells were passaged after reaching confluence. 
The cells were used between passage 2 and 4. 
 
2.1.2 Cell culture and infections 
Human Umbilical Vein EC (HUVEC) were maintained in M199 medium with 20% 
Fetal Bovine Serum, 1U/ml penicillin/0.1 mg/ml streptomycin, 2mM  L-glutamine, 3 
mg/ml Endothelial Cell Growth Factor (ECGF, Sigma) in heparin (1000 U/ml, CP 
Pharmaceutical) at 37° C and 5% CO2, in plates precoated with 1% gelatin (Sigma). 
Human Coronary Artery EC (HCAEC; Lonza) were grown in EBM-2 medium at 37° 
C and 5% CO2, in plates precoated with 1% gelatin, and used between passages 2 to 
7. 293A cell line was maintained in DMEM (Invitrogen) with 10% Fetal Bovine 
Serum (FBS; Sigma), 1U/ml penicillin/0.1 mg/ml streptomycin and 2mM L-
glutamine (Sigma). Cells were cultured in 75 cm
2
 flasks (Corning) and passaged 
every 3-4 days by trypsinization: they were washed twice with Hanks' Balanced Salt 
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Solution (HBSS, Sigma), incubated with 0.5 mg/ml trypsin in EDTA (MP 
Biomedicals) for 3 min at 37°C and 5% CO2 and resuspended in their specific 
growth medium. Human promyelocytic leukemia cell line (HL-60) was maintained 
in 75 cm
2 
flasks and cultured in Iscove's Modified Dulbecco's Medium (IMDM, 
Gibco), with 10% FBS, 1U/ml penicillin/0.1 mg/ml streptomycin and 2mM L-
glutamine at 37° C and 5% CO2. HL-60 cell density was maintained between 1 x 10
5
 
and 1 x 10
6
 cells/ml by dilution into fresh medium every 2-3 days. HUVEC or 
HCAEC (250,000 cells per 35-mm diameter well) were seeded one day before 
transduction and incubated with the specific viral multiplicity of infection (MOI) in 
EBM-2 medium (Lonza) (for 24 to 96 hours) or serum-free M199 (for 3 hours). 
EBM-2 medium was replaced 48 hours after infection. Serum-free M199 was 
removed after the infection, and replaced with complete M199 medium. 293A cells 
were plated one day before transfection and transfected in serum-free OptiMEM 
medium (Invitrogen) (to reach 85% confluence at the time of transfection) with 
Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. 
 
2.1.3 Delivery of Erg-specific Genebloc in HUVEC 
HUVEC (1x10
5
 cells per well) were seeded in a 35-mm diameter, 6-well dish in 
EGM-2 medium the day before transfection. Control (ctl) or Erg Genebloc (GB,
204
 
final concentration, 100 nM) and transfection lipid AtuFect01 (final concentration, 1 
μg/ml; Silence Therapeutics) were mixed at 5 times concentration in OptiMEM 
medium at 37°C for 30 minutes in polystyrene tubes. After incubation, the lipid/GB 
complexes were added to cells containing EBM-2 to give a 1x concentration, and 
incubated for the indicated period. 
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2.1.4 Inhibition of NF-kB in HUVEC with BAY 11-7085  
HUVEC (1x10
5
 cells per well) were seeded 39 hours before stimulation with BAY 
11-7085 (Sigma) in a 35-mm diameter, 6-well dish in EGM-2. They were treated 
with BAY 11-7085 (5 μM) diluted in DMSO for 24 hours. Stimulation of the cells 
was performed in EGM-2. 
 
2.1.5 Adenovirus generation 
ViraPower Adenoviral Expression System (Invitrogen) was used to generate p55 Erg 
adenovirus (AdErg). pAd/CMV/V5-Dest vector (Invitrogen) encoding for p55 Erg 
(Figure 12, kind gift of Dr. Mike Johns) was digested with Pac I enzyme (Invitrogen) 
to expose the inverted terminal repeats (ITRs), and transfected into the 293A cell 
line. After visible plaque formation, the cells were harvested. Virus was extracted by 
3 freeze/thaw cycles by keeping the tube at -80° C for 30 minutes, then at 37° C for 
15 minutes. The cell lysate was centrifuged at 1912 g for 15 minutes at room 
temperature to pellet cell debris. The supernatant (crude viral lysate, 200 μl) was 
used to amplify the virus by infecting 293A cells, grown until confluence in 175 cm
2
 
flasks (BD Falcon).  After 3 days, when plaque formation was visible, the cells were 
harvested and processed as described above to get an amplified crude viral lysate. 1 
μl of amplified and purified AdLacZ (Dr. Mike Johns) virus was used in the same 
way to amplify AdLacZ. Each virus was purified using Adeno-X Maxi Purification 
Kit (Clontech) as follows: when 293A showed cytophatic effect, cells were pelleted 
by centrifugation at 500 g for 10 minutes. Supernatant was discarded, and the cell 
pellet was resuspended in 5 ml of fresh medium. Cells were lysed with three 
consecutive freeze-thaw cycles: they were frozen in a dry ice/ethanol bath, then 
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thawed at 37°C. Lysates were cleared by centrifugation at 1,500 g for 5 minutes, and 
incubated with 5 ml Benzonase Nuclease for 30 minutes at 37° C. 1X Dilution 
Buffer (5ml) was added, and the lysate was clarified by filtering it through a 0.45 μm 
filtered Syringe-tip. Purification filter within the purification syringe was 
equilibrated with 5 ml 1X Equilibration Buffer, and the lysate was drawn into the 
syringe. Purification filter was washed with 20 ml 1X Wash Buffer. The adenovirus 
was eluted with 3 ml 1X Elution Buffer, sub-aliquoted and stored at -80 °C. 
 
2.1.6 Adenovirus titration 
AdErg and AdLacZ were titered by performing a plaque assay on 293A cells plated 
in 35-mm diameter, 6-well dish tissue culture plates. 293A cells (700,000 cells per 
well) were plated one day before infection. Serial dilutions of the adenoviral stock 
were prepared in growth medium and used to infect 293A cells overnight. The 
following day, medium containing virus was removed and replaced with prewarmed 
4% agarose in DMEM medium with 2% Fetal Bovine Serum, 1U/ml penicillin/0.1 
mg/ml streptomycin and 2mM  L-glutamine. 11 days after infection, the number of 
plaques in each dilution was counted. The titer of the adenovirus, expressed in plaque 
forming units (PFU)/ml, was calculated using the following formula: N. plaques/ (d x 
V), where d= virus dilution used to infect the cells, and V= volume of medium used 
to infect the cells. The volume of virus subsequently used to transduce EC cells was 
calculated using the following formula: number of infected cells x desidered 
multiplicity of infection (MOI) = Total PFU needed/PFU/ml = ml virus. 
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2.1.7 Viral DNA purification 
The crude viral lysate (see paragraph 2.4) was diluted 1:20 in PBS and boiled for 4 
minutes at 100°C. 100 µl of the sample were added to 50 µl phenol. After vortexing, 
50 µl chloroform were added to the mixture. The sample was centrifuged for 5 
minutes at 8000 g and the aqueous phase was removed. 22 µl sodium acetate (3M, 
Ph 5.5) and 1 ml ethanol 100% were added to the sample. The mixture was kept at -
20°C for 5 minutes and centrifuged at 8000 g for 5 minutes, 4°C. The ethanol was 
removed and replaced with 1 ml ethanol 80%. The sample was centrifuged at 8000 g 
for 5 minutes, 4°C, and the ethanol was removed. Once the DNA pellet was dried, it 
was resuspended in 20 μl molecular biology H2O (Sigma). 
 
2.1.8 Polymerase chain reaction (PCR) 
1 μl virus DNA was amplified using the following reagents: 5 µl 10X NH4 buffer 
(Bioline); 1.5 mM MgCl2  (Bioline); 0.2 mM DNTPs Mix; 0.3 µM 5'-forward Erg 3 F 
primer, 0.3 µM 3'-reverse pAd R primer; 1.5 units Biotaq Red DNA polymerase 
(Bioline). The DNA was denatured by heating the mixture at 94°C for 2 minutes, and 
amplified according to the following conditions, repeated for 30 cycles: 94°C for 15 
seconds, 55°C for 30 seconds, 72°C for 1 minute. PCR were performed using PTC-
100 thermocycler (MJ Research INC.). PCR products (20 µl) were analysed by 1% 
agarose gel electrophoresis and visualized by ethidium bromide staining and UV 
light transluminator (GelDoc IT, Bioimaging systems). 
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2.1.9 Antibodies 
Antibodies used in this study included: polyclonal antibodies (pAbs) anti-Erg (sc-
18136, sc-28680 and sc-353), anti-IκBα (sc-847), anti-HDAC-1 (sc-7872)  (all from 
Santa Cruz Biotechnology), anti-VWF (Dako), anti-CD31 (Ab 28364, Abcam), 
ICAM-1 (AF796), anti-MPO (AF3667), (both from R&D); monoclonal antibodies 
(mAbs) anti-GAPDH (mAb 374, Millipore), anti-p50 (sc-8414, clone E-10), anti-p65 
(sc-8008, clone F-6), anti-TNFR1 (sc-8436, clone H-5), (all from Santa Cruz 
Biotechnology), anti-V5 (46-0705, Invitrogen), anti VE-Cadherin (610252, BD 
Transduction Laboratories), anti-ICAM-1 (clone 15.2, kind gift of Prof. Nancy 
Hogg), and anti LFA-1 (clone TS1/22, kind gift of Prof. Dorian Haskard). Mouse 
IgG1 (eBioscience) were used as negative control. Secondary HRP labeled 
antibodies were: anti-mouse IgG (NA931V5, GE Healthcare), anti-rabbit IgG (7074, 
Cell Signaling) and anti-goat IgG (PO449, Dako). Secondary FITC labeled 
antibodies were: anti-mouse IgG (F0232, Dako) 
 
2.1.10 Immunoblotting 
2.1.10.1 Preparation of total cell lysates 
Cells were washed twice with 2 ml ice-cold PBS, harvested with 100 μl lysis buffer 
(0.5 % Triton X-100; 20 mM Tris-HCl PH 7.5; 150 mM NaCl; 0.5 mM 
Phenylmethylsulphonylfluoride, 1mM PMSF, protease inhibitor cocktail (SIGMA) 
(1:100)) and centrifuged for 15 min at 21912 g, 4°C. Supernatants were processed 
for SDS-PAGE. 
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2.1.10.2 Preparation of nuclear and cytosolic cell lysates 
Nuclear extract kit (Active Motif) was used to collect nuclear and cytosolic lysates 
from HUVEC. Cells were washed twice with 1 ml ice-cold PBS/Phosphatase 
inhibitors, harvested, centrifuged at 53 g for 5 minutes at 4°C. Cell pellet was 
resuspended in 500 μl Hypotonic Buffer, incubated 15 minutes on ice and vortexed 
after adding 25 μl Detergent. Suspension was centrifuged at 14000 g for 30 seconds 
at 4°C, and supernatant (cytoplasmic fraction) was collected. Pellet (nuclear fraction) 
was resuspended in 50 μl Complete Lysis Buffer, vortexed and incubated on ice on a 
rocking platform for 30 minutes. After vortexing, suspension was centrifuged at 
14000 g for 10 minutes at 4°C, and the pellet was discarded. 
2.1.10.3 Immunoprecipitation 
Protein G Sepharose beads (Sigma) were washed twice with washing buffer (0.1% 
Triton, 20 mM Tris-HCl PH 7.5; 150 mM NaCl; 0.5 mM PMSF) and centrifuged 1 
min at 15300 g, 4°C. Beads were loaded with 10μg of the indicated antibody diluted 
in washing buffer for 2 hours at 4°C, washed twice with washing buffer and 
centrifuged 1 min at 15300 g, 4°C. The indicated amount of lysate was added and 
incubated with beads in rotation for 2.5 hours at 4°C. Beads were washed 3 times 
with washing buffer for 1 min at 15300 g, 4°C, resuspended in Laemmli Sample 
Buffer (Biorad) with 0.7M 2-mercaptoethanol, boiled for 5 minutes at 100°C and 
used for SDS-PAGE. 
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2.1.10.4 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
Immunoblotting was carried out using 10 to 20 µg of total cell lysate. When nuclear 
and cytoplasmic lysates were prepared (see section 2.1.10.2), 7 ug of lysates were 
processed. Protein concentration of the lysates was determined with Bio-Rad protein 
assay (Biorad): the adsorbance of the samples was obtained with Synergy HT 
spectrophotometer (BIO-TEK). Samples were added to Laemmli Sample Buffer 
(Biorad) with 0.7M 2-mercaptoethanol and boiled for 5 minutes at 100°C. When 
samples were loaded in non-reduced conditions, 2-mercaptoethanol was omitted 
from Laemmli Sample Buffer. 
Proteins were separated by SDS-7% or 10% polyacrylamide gel electrophoresis 
(PAGE), transferred to PVDF membrane (Immobilon-P, Millipore), blocked with  
PBS-T milk (PBS with 0.1% Tween-20; 5% low-fat milk) for 1 hour at room 
temperature, and probed with the following antibodies, diluted in PBS-T milk: anti-
Erg (1:400); anti-GAPDH (1:30000); anti-V5 (1:2500); anti VE-Cadherin (1:1000); 
anti-ICAM-1 (1:1000); anti-p65 (1:500); anti-P-p65 (Ser-536; 1:1000); anti-P50 
(1:500); anti-TNFR1 (1:500). These antibodies were incubated with the membrate 
for 2 hours at room temperature, or overnight at 4° C. The membrane was rinsed in 
PBS-T, then washed once for 15 minutes and twice for 5 minutes with PBS-T. The 
membrane was incubated for 1 hour at room temperature with the following 
secondary antibodies conjugated with horseradish peroxidise (HRP): NA931 anti-
mouse/HRP (1:10000 in PBS-T, Amersham Biosciences), P0449 anti-goat/HRP 
(1:5000, Dako). The membrane was rinsed in PBS-T, then washed once for 15 
minutes and twice for 5 minutes with PBS-T. Detection was visualized by enhanced 
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chemiluminescence (Amersham Biosciences) and Kodak Biomax Light Film 
(Sigma). 
 
2.1.11 RNA isolation from HUVEC 
Cells were harvested with 350 μl RLT buffer (Qiagen) containing 3.5 μl 2-
mercaptoethanol. The lysate was passed 5 times through a blunt 20-gauge needle (0.9 
mm diameter) fitted to an RNase-free syringe. 1 volume of 70% ethanol was added 
to the homogenized lysate. The sample was transferred to an RNeasy spin column 
(Qiagen) placed in a 2 ml collection tube, and centrifuged for 15 seconds at 8000 x g. 
The flow-through was discarded. 350 μl Buffer RW1 (Qiagen) were added to the 
RNeasy spin column. The column was centrifuged for 15 seconds at 8000 g, and the 
flow-through was discarded. 30 Kunitz units of DNase I (Qiagen) diluted in RNase-
free water were added to 70 μl Buffer RDD (Qiagen), and added to the RNeasy spin 
column membrane. After 15 minutes 350 μl Buffer RW1 (Qiagen) were added to the 
RNeasy spin column. The column was centrifuged for 15 seconds at 8000 g, and the 
flow-through was discarded. 500 μl Buffer RPE (Qiagen) were added to the RNeasy 
spin column. The column was centrifuged for 2 minutes at 8000 g, and placed in a 
new 2 ml collection tube. 50 μl RNase-free water (Qiagen) were added to the spin 
column membrane. The column was centrifuged for 1 min at 8000 to elute the RNA. 
The purity and the concentration of the RNA were analyzed using Genway (Genova) 
spectrophotometer. 
 
 69 
2.1.12 First-Strand cDNA synthesis 
Total RNA (1µg) was added to 1µl oligo(dT)20 (50µM) and 1 µl 10 mM dNTP Mix 
(Invitrogen). The total volume of the reaction was adjusted with water to a final 
volume of 13µl. The mixture was heated to 65°C for 5 minutes and incubated on ice 
for 5 minutes. 4 µl 5X First-Strand Buffer (Invitrogen), 1 μl 0.1M Dithiothreitol 
(DTT), and 1 μl of SuperScript III Reverse Transcriptase (Invitrogen) were added to 
the mixture. The reaction was incubated at 50°C for 60 minutes and inactivated by 
heating it to 70°C for 15 minutes. 
 
2.1.13 Real-time PCR 
5 μl template cDNA (diluted 1:50) was amplified using the following reagents: 12.5 
µl Jumpstart Sybr Green Taq Readymix (containing 0.625 Taq DNA polymerase 
units, Sigma) or iQ Sybr Green Supermix (Bio-Rad), 5.5 µl H2O, 0.4 µM 5'-forward 
primer (ERG-F, IL-8 F, or ICAM-1 F), 0.4 µM 3'-reverse primer (ERG-R, IL-8 R, or 
ICAM-1 R). The DNA was denatured by heating the mixture at 95°C for 3 minutes, 
and amplified according to the following conditions, repeated for 50 cycles: 95°C for 
15 seconds, 60°C for 45 seconds. Real-time PCR were performed using iCycler IQ 
thermocycler (Biorad). The results were analysed using iCycler IQ optical system 
software (Biorad). 
 
2.1.14 Flow cytometry 
HUVEC (1x10
5
 cells per well) were plated in 35-mm diameter, 6-well dish tissue 
culture plates and treated with ctl or Erg GB for 48 hours (see paragraph 2.1.3) or 
with TNF-α (10 ng/ml; R&D Systems, Abingdon, UK) for 24 hours. Cells were 
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washed twice with HBSS, incubated with 0.5 mg/ml trypsin in EDTA for 3 min at 
37°C and 5% CO2, resuspended in EGM-2 medium, and processed at 4°C as follows: 
they were added to a FACS tube  and washed twice with wash buffer (HBSS + 1% 
FBS). After each wash, cells were vortexed and centrifuged at 850 g for 5 minutes. 
Primary antibodies (ICAM-1 15.2 or mouse IgG; 2 μg in 100ul wash buffer) were 
added to the cells and incubated for 30 minutes. As negative control, cells were not 
incubated with any primary antibodies. HUVEC were washed twice with wash 
buffer. After each wash, cells were vortexed and centrifuged at 850 g for 5 minutes. 
FITC labeled anti-mouse secondary antibodies (2 μg in 100ul wash buffer; Dako) 
were added to the cells and incubated in the dark for 30 minutes. HUVEC were 
washed twice with wash buffer and twice with PBS. Cells were resuspended in 1% 
paraformaldehyde (PFA) in PBS for 15 minutes, and analysed with CYANADP 
cytofluorimeter (Beckman Coulter) for ICAM-1 surface expression detection. Data 
were analysed with Summit 4.3 software (Beckman Coulter). 
 
2.1.15 Reporter gene assays 
HUVEC were seeded at 3 x 10
4
 per well in EBM-2 medium on a gelatin-coated 24 
well plate, then transduced with AdErg or AdLacZ (50 MOI) and maintained in 
EBM-2 medium. After 24 hours, co-transfection of HUVEC was performed with 
Genejuice transfection reagent (Merck Chemicals), according to the manufacturer’s 
instructions. Briefly, cells were incubated with 1.5 µl GeneJuice, 250ng pGL4 
ICAM-1 1.3 or pGL4.10 empty vector and 250ng pGL4.73 Rluc/TK Renilla 
Luciferase (Promega) for 24 or 48 hours. For the final 6 hours of each time point, the 
EBM-2 medium was replaced with fresh EBM-2 supplemented with 10ng/ml TNF-α. 
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In some experiments, the ICAM-1 promoter reporter assay was performed on cells 
previously transfected with Erg or ctl GB. Twenty-four hours after GB treatment, 
cells were transfected with the reporter constructs and luciferase activities were 
measured after a further 24 hours. NF-kB transcriptional activity was measured using 
a pGL2 NF-kB luciferase reporter plasmid.
214
 HUVEC (3 x 10
4
 cells per well in a 
24-well plate) were transduced with AdErg or AdLacZ (50 MOI) and maintained in 
EBM-2 medium. After 24 hours, cells were co-transfected with 250 ng pGL2 NF-kB 
or pGL2 empty vector and 250 ng pGL4.73 Rluc/TK and incubated for 48 hours. Six 
hours before measurement of NF-kB activity, the EBM-2 medium was replaced with 
fresh EBM-2 supplemented with 10ng/ml TNF-α. Transfected cells were washed 
twice with PBS and lysed in 100 μl 1X passive lysis buffer (Promega). Plates were 
incubated at room temperature for 15 minutes with gentle rocking prior to scraping. 
20 μl of cell lysate was mixed with 100 μl LARII and 100 μl Stop-Glo reagents 
(Promega). Luciferase activity was measured with on a Syngergy HT microplate 
reader. For the experiment shown in Figure 14 B, Hela (5 x 10
4
 cells per well in a 24-
well plate) were co-transfected with 100 ng pGL2 NF-kB or pGL4 empty vector, 100 
ng pGL4.73 Rluc/TK, and 100 ng pcDNA3.1 or pcErg3. Cells were incubated for 24 
hours, and then stimulated with TNF-α (10 ng/ml) or left unstimulated for a further 
16 hours, before being assessed for luciferase activity as described above.  
 
2.1.16 Leukocyte adhesion assay 
HUVEC (3x10
4
 cells/well) grown in M199 medium on 1% gelatin-coated 96-well 
plates, were transduced with AdErg or AdLacZ (MOI: 50). After 24 hours, cells were 
stimulated with TNF-α (10 ng/ml) for a further 24 hours. HL-60 were used when 80-
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90% confluent. Cells were centrifuged at 478 g for 5 minutes, resuspended in growth 
media to a final concentration of 6x10
6
 cells/ml, and incubated with 10μM 2′,7′-
Bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF, Sigma) for 10 minutes at 
37°C. Cells were centrifuged at 478 g for 5 minutes and resuspend in HBSS 
containing 0.01% BSA (Sigma) and 1 mM K
+
 EDTA (Sigma). They were 
centrifuged at 478 g for 5 minutes and resuspend in HBSS containing 0.01% BSA, 
then centrifuged in the same way and resuspended in HBSS to a final concentration 
of 6x10
6
 cells/ml, and incubated with 1mM MnCl2. HUVEC growth media was 
replaced with 50 μl HBSS. 50 μl of HL-60 suspension were added to HUVEC and 
incubated for 30 minutes at 37°C. Wells were gently washed 4 times with 200 μl 
HBSS containing 0.01% BSA. Adherent HL-60 cells were quantified by lysing the 
cells in each well with 100 μl Triton X-100 (2%) and measuring fluorescence on a 
Synergy HT microplate reader using a 485/535nm filter. 
 
2.1.17 NF-κB DNA binding assay 
HUVEC cultured in 35-mm diameter, 6-well dish tissue culture plates and 
transduced with either AdLacZ or AdErg (MOI: 50) were treated with TNF-α 10 
(ng/ml) for 30 minutes or left untreated. Nuclear fractions were harvested from cells 
using the nuclear extract kit (Active Motif; see above paragraph 2.1.10.2). To 
quantify the binding of P65 NF-κB subunit for the specific TNF-induced NF-kB 
responsive sequence on the ICAM-1 promoter, I generated a biotinylated 51 bp 
oligonucleotide containing a functional NF-kB binding site
99
 and a putative ETS 
binding sequence (Matinspector software bioinformatical analysis) (ICAM-1 biotin-
F, Table 2). The binding experiments were performed using the Transam Flexi kit 
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(Active Motif). 7 μg of nuclear lysate were added to 50 μl Complete Binding Buffer 
and 1 pmol biotinylated oligonucleotide. As a positive control, the assay was 
performed using a biotinylated double stranded oligo containing a NF-κB consensus 
binding site (5'- GGGACTTTCC-3') and 5 μg of Jurkat nuclear extract (Active 
Motif). Suspensions were incubated at room temperatue for 30 minutes, added to a 
streptavidin coated plate and incubated for 1 hour at room temperature with mild 
agitation. Wells were washed 3 times with 200 μl 1X Wash buffer. 100 ul diluted 
NF-κB antibody (1:1000 in 1X antbody binding buffer) was added to the wells, and 
the plate was incubated for 1 hour at room temperature. Wells were washed 3 times 
with 200 μl 1X Wash buffer, and 100 ul diluted HRP antibody (1:1000 in 1X 
antbody binding buffer) was added. Plate was incubated for 1 hour at room 
temperature. Wells were washed 4 times with 200 μl 1X Wash buffer and 100 μl 
Developing solution were added. The plate was incubated 10 minutes in the dark, 
and 100 μl Stop solution were added. Adsorbance was read at 450 nm on a Synergy 
HT microplate reader. 
 
2.1.18 Chromatin immunoprecipitation (Dryden N.) 
Chromatin immunoprecipitation (ChIP) was performed using ChIP-IT (Active Motif, 
Rixensart, Belgium) as previously described (Birdsey et al 2008). Briefly, sheared 
chromatin from pooled HUVEC was added to 2µg Erg antibody (sc-353) or negative 
control rabbit IgG. Immunoprecipitated DNA was then used as template for 
quantitative PCR using primers specific for the ICAM-1 promoter sequence (ICAM 
1 Prom), to amplify a region containing the TNF-α-responsive NF-kB binding site. 
To determine the specificity of the Erg chromatin interactions, PCR amplification 
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was also carried out with primers downstream of the promoter in a region that should 
not interact with transcription factors (ICAM-1 Ctrl). Data is presented as the 
percentage of immunoprecipitated template compared to the total input sample (See 
Table 2 for oligonucleotide sequences). 
 
2.1.19 Paw Swelling Model of Acute Inflammation (Madden L.) 
All experiments used 8-weeks old C57BL/6J mice, from Harlan Laboratories UK 
(Blackthorn, Bicester, UK). Mice were maintained at the Biological Service Unit of 
the Kennedy Institute of Rheumatology. Studies were performed in accordance with 
the UK Animals (Scientific Procedures) Act 1986, under Home Office Project 
Licence no: 70/5446. Animals (5 mice/group) received a single intraplantar injection 
of AdErg or AdLacZ (10
7
 plaque forming units, PFU). In a separate set of 
experiments, animals received an intraperitoneal injection of anti-ICAM-1 (100 μg), 
(Thermo Scientific, Rockford, USA) or isotype control antibody (Insight 
Biotechnology Ltd, Middlesex UK). 24 hours later, mice received an intraplantar 
injection of murine recombinant TNF-α (50ng in 10µl of PBS), (PeproTech, Inc, 
Rocky Hill NJ, USA) or PBS (10µl) as control. Paw swelling was measured over 24 
hours with microcalipers (Röhm BG Ltd, Kingston-upon-Thames, UK). At the 
conclusion of the experiment, paws were dissected post-mortem and snap frozen in 
liquid nitrogen prior to RNA extraction. RT-PCR was performed using Erg-V5 F and 
Erg-V5 R primers (Table 3), spanning the region across the Erg-V5 fusion. 
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2.1.20 Immunohistochemistry (Madden L., Boyle J.) 
Human plaques were from a series of paraffin-embedded plaques that derive from 
West of Scotland hospital autopsies.
215
 Immunostaining was carried out as 
described.
216
 Sections were incubated with anti-Erg (sc-353; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) or anti-VWF (Dako, Glostrup, Denmark). 
Antibody complexes were detected using 3,3-diaminobenzidine tetrahydrochloride 
(DAB, Sigma) and hematoxylin counterstaining. Hind feet of mice were excised after 
euthanasia and fixed in 10% buffered formalin solution. Fixed specimens were 
decalcified (Rapid-CalTM; BBC Biochemical, Dallas, TX, USA) and embedded in 
paraffin wax. Serial sections were stained with haematoxylin and eosin (H&E). 
Further slides were stained with antibodies to myeloperoxidase (MPO), ICAM-1 
(both from R&D), CD31 (Ab-28364), (Abcam, Cambridge, UK) and Erg  (sc-353), 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
 
2.1.21 Statistical analysis 
Results were expressed as mean  SEM and analysed using GraphPad Prism 4.0 
(Graph Pad Software, CA, USA). Data were analysed using Student T-Test. Data 
from the paw swelling experiment were analysed using two-way analysis of variance 
(ANOVA). P values less than 0.05 were considered to be statistically significant. 
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Chapter 2, Figure 1. Map of the vector used to generate p55 Erg adenovirus. attR1, 
attr2: recombination sequences allowing the cloning of p55 Erg into pAd/CMV/V5-
DEST vector. ITR: Viral inverted terminal repeat. Pcmv: CMV promoter. TK Pa: 
Herpes Simplex Virus thymidine kinase polyadenylation signal. Puc ori: Puc origin, 
sequence allowing high-copy and replication of the vector in E. coli (adapted from 
“pAd/CMV/V5-DEST Gateway Vector” instruction manual, Invitrogen). 
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NAME SEQUENCE 
ERG F 5’-GGAGTGGGCGGTGAAAGA-3’ 
ERG R 5’-AAGGATGTCGGCGTTGTAGC-3’ 
ICAM-1 F 5’-CTGAAACTTGCTGCCTATTGGG-3’ 
ICAM-1 R 5’-ACACATGTCTATGGAGGGCCA-3’ 
VCAM F 5’-CTACGCTGACAATGAATC-3’ 
VCAM R 5’-GCAACTGAACACTTGAC-3’ 
IL-8 F 5’-CAGAGACAGCAGAGCACAC-3’ 
IL-8 R 5’-AGTTCTTTAGCACTCCTTGGC-3’ 
GAPDH F 5’-CAAGGTCATCCATGACAACTTTG-3’ 
GAPDH R 5’-GGGCCATCCACAGTCTTCTG-3’ 
ERG-V5 F 5’-CTCCAGCCCTCCCCGTGACA-3’ 
ERG-V5 R 5’-TTCGAACCGCGGGCCCTCTA-3’ 
Erg3 F 5’-CACCATGATTCAGACTGTCCC-3’ 
Erg3 R 5’-GTAGTAAGTGCCCAGATGAG-3’ 
ICAM-1 biotin-F 5’-Biotin-
ATCGCCCTGCCACCGCCGCCCGATTGCTTT 
AGCTTGGAAATTCCGGAGCTGA-3’ 
ICAM-1 Reverse 5’-
TCAGCTCCGGAATTTCCAAGCTAAAGCAATCGGGCGG 
CGGTGGCAGGGCGAT-3’ 
ICAM-1 Prom F 5’-TTGGAAATTCCGGAGCTGAAGC-3’ 
ICAM-1 Prom R 5’-GGGCGCGTGATCCTTTATAGC-3’ 
ICAM-1 Ctrl F 5’-TGTGTAGCATCAAAACACAAAG-3’ 
ICAM-1 Ctrl R 5’-ACCTTGAATGTGATTAGGACTGG-3’ 
NF-kB R 5’-AGATCTAAGTAAGCTTGGCATT-3’ 
 
Table 1. List of the primers used for PCR , Real-Time PCR and NF-κB DNA binding 
assay. 
 
NAME SEQUENCE 
pAd F TAATACGACTCACTATAGGG 
pAd R ACCGAGGAGAGGGTTAGGGAT 
Erg 3-For CACCATGGCCAGCACT 
Erg Rev AGTAGTAAGTGCCCAGATGAG 
Erg-Mid-For AGGAACTGTGCAAGATGAC 
Erg Exon72-For ATATCCTGAAGCTACGCAAAG 
 
Table 2. List of the primers used for pAd/CMV/V5-Dest vector sequencing. 
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2.2 Tools generation  
2.2.1 Cloning, generation and expression of Erg adenovirus 
Adenoviral delivery is commonly used to get high levels of transduction in cells, 
such as HUVEC, which are not easily transfectable with plasmids at high efficiency 
using lipidic reagents. Moreover, delivery of adenoviral vectors is a promising 
approach in gene therapy.
217
 p55 Erg adenovirus (AdErg), was generated to assess 
the Erg effects on inflammation in EC, both in vitro and in vivo. In order to do this, 
ViraPower Adenoviral Expression System (Invitrogen) was used (the process is 
schematically summarized in Chapter 2, Figure 2). Blunt ended PCR products were 
derived from HUVEC cDNA amplified with primers against p55 Erg. They were 
cloned into a pENTR TOPO vector (Invitrogen) to generate an entry clone, suitable 
for recombination. The recombination reaction was performed between the entry 
clone and the destination vector pAd/CMV/V5-Dest vector (Invitrogen) (the 
procedure described above was carried out by Dr. Mike Johns). pAd/CMV/V5-Dest 
vector (Invitrogen) encoding p55 Erg was checked by sequencing (see Table 3 for a 
list of the primers used), digested with Pac I enzyme (Invitrogen) and transfected 
into the 293A cell line. After visible plaque formation (Chapter 2, Figure 3 B-C), the 
cells were harvested and a crude viral lysate was prepared. AdErg was amplified by 
infecting 293A cells with the crude viral lysate. The infection was allowed to 
proceed until 90% of the cells had rounded up and were floating (Chapter 2, Figure 3 
D). The virus was purified and titered by measuring the numbers of plaques formed 
by infected 293A cells in an agarose overlay solution (see “Materials and methods” 
section; Chapter 2, Figure 3 E). The virus concentration was calculated to be 3.3x10
9 
PFU/ml. In order to confirm the presence of V5-Erg DNA sequence in the virus, the 
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viral lysate was purified using a phenol/chloroform procedure, followed by PCR 
amplification using primers annealing to the Erg 5' and V5 3' sequences. The 
amplified DNA was processed for agarose gel electrophoresis, and a band with the 
expected molecular weight was identified (Chapter 2, Figure 4). 
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Chapter 2, Figure 2. Flow diagram describing the steps followed for the generation of 
p55 Erg adenovirus (AdErg) (adapted from “ViraPower Adenoviral Expression 
Syestem” user manual, Invitrogen).  
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Chapter 2, Figure 3. Phase-contrast pictures showing different phases of AdErg 
production in 293A cells. A, non infected 293A cells confluent monolayer. B, 
patches of rounded 293A cells producing adenovirus. C, infected 293A cells 
detaching from an infected plaque. D, virus-loaded 293A cells floating in the cell 
medium. E, plaque formed by infected 293A cells overlaid by agarose solution. 
Pictures were taken using a 10X objective. 
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Chapter 2, Figure 4. Erg-V5 insert is present in the AdErg viral lysate. PCR was 
performed on purified DNA from 293A cells transfected with p55 Erg-
pAd/CMV/V5-DEST vector using primers flanking 5'-Erg and 3'-V5 regions. 
Positive control, plasmid DNA used to transfect 293A cells. Negative control, 
purified DNA from non infected 293A cells lysate. H2O, PCR performed by 
replacing DNA with the same volume of H2O. Molecular weight expressed in Kb. 
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2.2.2 Biochemical characterization of exogenous Erg expression 
in HUVEC  
To characterize the effect of the exogenous Erg gene delivery in ECs, HUVEC were 
transduced with increasing amounts of AdErg. As expected, AdErg transduction 
resulted in the expression of a band with molecular weight of 55 kDa. Moreover, 
both exogenous and total Erg expression levels were proportional to the virus MOI 
used for the transduction, indicating that the over-expression of the transgene was 
effective (Chapter 2, Figure 5, Chapter 2, Figure 6). When the samples were analysed 
with an antibody to endogenous Erg, an Erg band ranging between ≈45 and ≈60 kDa 
was detected, suggesting that this protein might be the target of post-translational 
modifications. Interestingly, Erg over-expression produced an extra band of apparent 
molecular weight ≈70 kDa, whose intensity increased in parallel with higher MOI 
transduction (Chapter 2, Figure 5). The 70 kDa band was not recognized by western 
blot using an antibody anti-V5 (Chapter 2, Figure 6), suggesting that the V5 epitope 
is cleaved from the 70 kDa band. To identify whether the 70 kDa band was specific 
for Erg, Erg was immunoprecipitated from either AdErg-transduced or not 
transduced HUVEC. Western-Blot analysis was carried out on the 
immunoprecipitated and total cell lysates, using an Erg antibody raised against a 
different epitope from the one used to immunoprecipitate Erg. Erg immunoblotting 
visualized the 70 kDa band selectively in the immunoprecipitated fractions and total 
cell lysates from AdErg transduced cells (Chapter 2, Figure 7 A lanes 3, 4, 8). To 
further verify that this band was Erg-specific, it was isolated from an SDS-PAGE gel 
and analyzed by matrix-assisted laser desorption/ionization–quadrupole time-of-
flight (MALDI QTOF). This analysis highlighted 8 peptides which corresponded to 
the predicted Erg aminoacidic sequence encoded by the AdErg construct (Chapter 2, 
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Figure 7 B). Interestingly, by matching the mass spectrometry results with a Homo 
sapiens peptide database, the following protein hits were also identified, all 
belonging to the Heat shock protein (HSP) 70 family: Heat shock 70 Kda protein 9B 
variant, dnaK-type molecular chaperone HSPA5 precursor, Heat shock 70 kDa 
protein 8, and Heat shock 70kDa protein 6. This result suggests that these proteins 
might co-associate with the AdErg encoded Erg protein, forming a high molecular 
weight complex of 70kDa which can't be denatured by SDS. The 70kDa Erg protein 
was not detected in HUVEC under physiological conditions (Chapter 2, Figure 5 A, 
non infected sample). Because the HSP70 family of proteins is involved in both 
protein folding and degradation,
218
 it is possible that the 70kDa Erg protein is 
degraded after being expressed. This might explain why this band is not detected by 
the V5 antibody, which conversely detects successfully the 55 kDa Erg band.  
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Chapter 2, Figure 5. Total Erg protein level is enhanced by p55 Erg adenovirus 
infection. HUVEC were infected with the indicated amount of AdErg. Cells were 
lysed and 20 µg of the cell lysate were analysed. Proteins were separated by SDS-
PAGE (10%) and probed with polyclonal anti-Erg (A) and monoclonal anti-GAPDH 
(B) antibodies. p55 Erg protein expression is quantified relative to GAPDH and 
normalized against the non infected (NI) sample (C). N=1 
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Chapter 2, Figure 6. Exogenous Erg protein levels are enhanced by p55 Erg 
adenovirus infection over dose-response course. HUVEC were infected with the 
indicated amount of AdErg. 48 hours after the infection the cells were lysed and 20 
µg of the cell lysate were analysed. Proteins were separated by SDS-PAGE (10%) 
and probed with monoclonal anti-V5 (A) and monoclonal anti-GAPDH (B) 
antibodies. V5 protein expression is quantified relative to GAPDH and normalized 
against HUVEC infected with 5 MOIs of p55-Erg adenovirus (C). N=1  
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Chapter 2, Figure 7. Analysis of 70 kDa band encoded by AdErg. 500 μg of cell 
lysate from AdErg infected cells or not infected cells (NI) were immunoprecipitated 
with rabbit polyclonal antibodies to Erg (sc-28680), and proteins were separed by 
SDS-PAGE. A, immunoprecipitates (IP), and equal amounts of lysates (TCL) and 
unbound fractions after immunoprecipitations (Ub) were probed using goat 
polyclonal antibodies anti-Erg (sc-18136). B, predicted aminoacidic sequence 
encoded by AdErg. After MALDI-QTOF examination (experiment carried out by Dr. 
Geeta Patel, Proteomics Core Facility, Imperial College, London) of the 70 kDa band 
(lane 8, A), sequences in red-bold were identified by MALDI analysis, sequences 
red-underlined were identified by QTOF analysis. Yellow dotted line: linker 
sequence between Erg C-terminus and V5 epitope. Yellow box: V5 epitope 
sequence. 
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CHAPTER 3: RESULTS  
 
3.1 Erg as a repressor of pro-inflammatory genes 
 
3.1.1 Erg downregulation increases the expression of ICAM-1 
Because of the importance for endogenous Erg levels to maintain homeostasis in EC, 
a gene array study was performed in our laboratory to analyse gene expression 
profiles of HUVEC where Erg was inhibited. To do this, an Affymetrix Human 
Genome U133 Plus 2.0 array was used to compare significantly different expression 
values of genes, in cells treated with an antisense oligonucleotide (Genebloc or GB) 
specific for Erg or a control antisense, for 24 or 48 hours. Data analysis, performed 
with  Rosetta Resolver  (v 7.1) showed that Erg downregulation leads to an increased 
expression of a number of pro-inflammatory genes (Birdsey G. and Randi A.M., 
submitted to Blood). Particularly, mRNA levels of the ICAM-1 molecule showed a 
2.11 fold increase after 48 hours of Erg inhibition compared to the control. This data 
suggests a role for Erg in repressing basal endothelial activation. To confirm this, Erg 
levels in EC were decreased using the same antisense oligonucleotide mentioned 
above, specific for Erg (GB 566), and either Erg mRNA or protein levels were 
measured after 48 hours of GB treatment. As a control, to show that the GB was 
specific for Erg, an oligonucleotide antisense designed to the same region of the Erg 
gene but containing 4 mismatches (GB 478) was used. This approach is established 
and has been extensively characterized in previous studies.
179;204
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3.1.1.1 Analysis of Erg and ICAM-1 mRNA levels after Erg 
inhibition by GB 
To validate the microarray data which indicates a potential role for Erg in repressing 
ICAM-1 expression (see above) RT-PCR analysis was performed. HUVEC were 
cultured for 48 hours in the presence of either Erg or control GB. Following mRNA 
extraction and cDNA synthesis, quantitative RT-PCR was carried out to determine 
levels of Erg and ICAM-1. Inhibition of Erg expression in HUVEC using antisense 
GB, which decreased Erg levels by ≈80% (Chapter 3, Figure 1 A), resulted in a 6-
fold upregulation of ICAM-1 mRNA levels (Chapter 3, Figure 1 B). These results 
suggest that Erg can act as a repressor of basal ICAM-1 expression. 
 
 
 
 
Chapter 3, Figure 1. Erg represses basal ICAM-1 mRNA expression in HUVEC. 
HUVEC were transfected with either Erg or control (ctl) Genebloc (GB). mRNA 
levels for Erg (A) and ICAM-1 (B) were measured after 48 hours; all data is 
normalized to GAPDH. n=3. **P<0.01  
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3.1.1.2 Regulation of ICAM-1 protein levels after Erg GB 
To confirm the Erg repression of basal ICAM-1 expression, ICAM-1 protein levels 
were measured in HUVEC treated with Erg or control GB. The same lysates were 
analysed for Erg expression, and the results normalized to GAPDH. As expected, Erg 
GB decreased Erg protein levels to about 20% of control (Chapter 3, Figure 2A). 
ICAM-1 protein expression was upregulated ≈2.5 fold compared to control (Chapter 
3, Figure 2 B). This shows that the Erg and ICAM-1 protein expression profiles are 
in line with the results obtained from the mRNA studies (see above, paragraph 
3.2.1.1). 
 
 
 
Chapter 3, Figure 2. Erg represses basal ICAM-1 total protein expression in HUVEC. 
HUVEC were transfected with either Erg or ctl GB. Total protein levels for Erg (A) 
and ICAM-1 (B) were measured after 40 hours; all data is normalized to GAPDH. 
n=4. **P<0.01; ***P<0.001 
 
 
 
 91 
3.1.1.3 Regulation of ICAM-1 surface levels after Erg GB 
ICAM-1 is a cell surface molecule.
219
 Therefore ICAM-1 surface levels were 
analysed by FACS on HUVEC treated with Erg or control GB for 48 hours. As 
positive control, ICAM-1 surface expression was also measured in HUVEC treated 
with TNF-α (10 ng/ml) for 24 hours (Chapter 3, Figure 3 A, E). As negative controls, 
FACS was performed using either isotype control antibodies or secondary FITC-
labelled antibodies for all the conditions analysed (Chapter 3, Figure 3 B, C, D, E). 
TNF-α treatment induced a 10 fold increase of ICAM-1 surface levels over control 
GB treated cells. Similarly to what found for the Erg regulation of ICAM-1 total 
protein levels (see paragraph 3.1.1.2), Erg GB treatment led to a 3 fold increase over 
control GB treated cells (Chapter 3, Figure 3 A). This result further confirms that 
basal ICAM-1 expression is repressed by Erg in resting cells and suggests that this 
effect might be functionally relevant.  
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Chapter 3, Figure 3. Erg represses basal ICAM-1 surface levels in HUVEC. A, Left 
panel: representative FACS profiles of HUVEC treated with ctl GB (filled line), Erg 
GB (black line) or TNF-α (dotted line). Right panel: mean fluorescence intensity 
relative to ctl GB. n=3. *P<0.05 
Representative FACS profiles of untreated HUVEC (B), and HUVEC treated with 
ctl-GB (C), Erg GB (D) or TNF-α (E). Filled line, FITC-labelled secondary antibody 
only. Black line, isotype control antibody. Dotted line, ICAM-1 antibody. n=1.  
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3.1.1.4 Regulation of ICAM-1 transcriptional activity after Erg GB 
To determine whether Erg represses constitutive ICAM-1 transcription in EC, an 
ICAM-1 luciferase reporter assay was used. HUVEC were treated with Erg or 
control GB for 24 hours, followed by transfection for 24 hours with either ICAM-1 
promoter luciferase reporter, or an empty vector luciferase construct (pGL4) as 
negative control. As shown in Chapter 3, Figure 4, ICAM-1 promoter activity was 
induced by Erg inhibition. This result shows that Erg represses ICAM-1 at the 
transcriptional level. 
 
 
 
 
Chapter 3, Figure 4. Erg represses basal ICAM-1 promoter activity in HUVEC 
(experiment carried out by Nicky Dryden). Luciferase activity in HUVEC treated 
with Erg GB for 24 hours, followed by transfection with ICAM-1 promoter 
luciferase reporter for 24 hours. Values are represented as fold change over control. 
n=8. *P<0.05; **P<0.01; ***P<0.001.  
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3.1.1.5 Regulation of ICAM-1 expression after Erg GB and NF-kB 
inhibition 
NF-kB is expressed, at low levels, in the nucleus of resting cells,
124;220
 and has been 
implicated in driving constitutive gene expression of target genes.
180;221
 The ICAM-1 
promoter contains 2 NF-kB binding sites.
78
 Among these, only the NF-kB binding 
site proximal to the transcription starting site is functional, and is overlapping with a 
putative ETS site recognised by a bioinformatic analysis (Chapter 1, Figure 4).
99
 
Analysis of human and mouse sequences of the 206 bp upstream of the 
transcriptional start site of the ICAM-1 promoter identified seven conserved putative 
EBS (Chapter 1, Figure 4). Although little is known about the regulation of basal 
ICAM-1 expression by NF-kB, a study has reported that NF-kB p65 deficiency leads 
to increased ICAM-1 protein levels.
222
 Because Erg represses basal ICAM-1 
transcription (see paragraphs 3.1.1.1 to 3.1.1.4) we hypothesized that Erg could 
repress basal NF-kB-mediated induction of ICAM-1. To investigate the role of NF-
kB in the ICAM-1 regulation by Erg, BAY 11-7085 (Sigma) NF-kB inhibitor was 
used in HUVEC, previously treated either with Erg or control GB. BAY 11-7085 
prevents the phosphorylation and the subsequent degradation of IkB-α, thus 
inhibiting NF-kB translocation into the nucleus and its activation of pro-
inflammatory genes.
223
 As a positive control for the inhibition of ICAM-1 induction 
by TNF-α, cells pretreated with either BAY 11-7085 or DMSO were stimulated with 
TNF-α (10 ng/ml) for 24 hours. Western blots were performed to analyse ICAM-1 
protein levels in these samples. As expected, BAY 11-7085 significantly inhibited 
TNF-α-induced ICAM-1 expression (Chapter 3, Figure 5; lanes 1, 2). In cells where 
Erg expression was inhibited, ICAM-1 levels were increased compared to cells 
treated with ctl GB, confirming the results shown in Chapter 3, Figure 2. However, 
 95 
this increase was repressed by the BAY compound (Chapter 3, Figure 5; lanes 3, 6). 
This suggests that the increase of ICAM-1 protein levels due to Erg downregulation 
is at least partially regulated by the NF-kB pathway. Therefore, this results points to 
a potential role for Erg in repressing the constitutive NF-kB signaling cascade. 
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Chapter 3, Figure 5.  A, upregulation of ICAM-1 after Erg Genebloc is repressed by 
the Nf-kB inhibitor BAY-117085. HUVEC were treated for 15 hours with either Erg 
(lanes 3, 6) or control (lanes 4, 7) Genebloc. The medium was replaced and cells 
were cultured for 24 hours in the presence of Bay-117085 (5μM) or DMSO. For the 
control experiment HUVEC were pretreated for 1 hour with Bay-117085 (5μM) or 
DMSO followed by 23 hours incubation with TNF-α (10 ng/ml) (lanes 1, 2). Cells 
were lysed and 20 μg of the cell lysate were analysed. Proteins were separed by SDS-
PAGE (10%) and probed with monoclonal anti-ICAM-1 and anti-GAPDH 
antibodies. ICAM-1 protein expression is quantified relative to GAPDH and 
normalized against HUVEC treated with control Genebloc and DMSO. 
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3.1.2 Erg over-expression inhibits basal expression of pro-
inflammatory molecules in EC. 
3.1.2.1 Analysis of ICAM-1, IL-8 and VCAM-1 mRNA levels after 
Erg over-expression by adenovirus 
In order to confirm the findings which highlight Erg as a novel repressor of basal 
pro-inflammatory gene expression, such as the ICAM-1 gene, I took the opposite 
approach. If ICAM-1 basal expression is induced by Erg down-regulation, ICAM-1 
levels would be expected to be reduced after Erg over-expression. To test this, an 
adenovirus encoding for p55 Erg (AdErg) was generated (see “Materials and 
methods, tools generation” section), and used to over-express Erg in HUVEC.  
HUVEC were transduced with either AdLacZ or AdErg for 48 hours. As expected, 
Erg mRNA levels were increased by Erg over-expression (Chapter 3, Figure 6 A), 
and ICAM-1 mRNA levels were reduced in the same conditions. Because the NF-kB 
pathway seems to be involved in inducing basal ICAM-1 levels following Erg 
downregulation (paragraph 3.1.1.5), and because some NF-kB related genes were 
found to be targets of Erg in the microarray study mentioned in paragraph 3.1.1 and 
in a recent study (see below, paragraph 3.1.4.6, and
182
), the expression of other pro-
inflammatory NF-kB target proteins was measured in Erg over-expressing cells. 
Interestingly, the basal expression of VCAM-1 and IL-8 was also inhibited by Erg 
over-expression, indicating a role for Erg in repressing other NF-kB related pro-
inflammatory genes involved in the regulation of leukocyte adhesion to the 
endothelium (Chapter 3, Figure 6 B). The fact that Erg over-expression leads to IL-8 
repression is also in line with a recent study showing that IL-8 levels are increased by 
Erg downregulation in HUVEC.
182
 
 98 
 
 
 
 
Chapter 3, Figure 6. Pro-inflammatory gene expression is repressed by Erg over-
expression in resting HUVEC. Erg (A), ICAM-1, VCAM-1 and IL-8 (B) mRNA 
levels in HUVEC transduced with either AdLacZ or AdErg for 48 hours. mRNA 
levels were normalized to GAPDH and shown as fold change over AdLacZ 
transduction. n=3 to 4. *P<0.05; **P<0.01; ***P<0.001 
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3.1.2.2 Analysis of ICAM-1 protein levels after Erg over-expression 
by adenovirus in HUVEC 
To confirm that Erg over-expression represses ICAM-1 at the protein level, HUVEC 
were transduced with AdErg or control adenovirus for 48 hours. Lysates were 
processed for immunoblotting. Expression of the exogenous proteins encoded by the 
two adenoviruses was tested by western-blot using anti-V5 antibodies (Chapter 3, 
Figure 7 A). ICAM-1 basal protein expression was significantly reduced by Erg 
over-expression, when comparing AdErg to either AdLacZ transduced cells or not-
transduced cells (Chapter 3, Figure 7 B). Transduction with control virus AdLacZ led 
to a small but significant increase in ICAM-1 levels, when compared to mock 
infected cells (Chapter 3, Figure 7 B). This might be due to a transient activation of 
EC by adenovirus
217
 which is not in conflict with our results, since AdErg has an 
opposite effect on ICAM-1 levels. Moreover, using a lower dose of adenovirus 
(MOI: 10) this nonspecific effect did not occur, while ICAM-1 repression by AdErg 
was maintained (Chapter 3, Figure 7 C). These results confirm that Erg is a repressor 
of constitutive ICAM-1 expression. 
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Chapter 3, Figure 7. ICAM-1 protein levels are decreased by Erg over-expression in 
resting HUVEC. Virus-encoded proteins detected by western blot in (A) with an 
antibody to V5. ICAM-1 total protein levels were normalized to GAPDH and shown 
as fold change over AdLacZ transduction. C, ICAM-1 protein levels from HUVEC 
transduced with a lower dose of adenovirus (MOI: 10). n=3. *P<0.05; **P<0.01; 
***P<0.001 
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3.1.2.2 Analysis of ICAM-1 protein levels after Erg over-expression 
by adenovirus in HCAEC 
To confirm that the effect of Erg over-expression on ICAM-1 protein levels was not 
restricted to HUVEC, ICAM-1 protein levels were also measured in HCAEC. The 
expression of the exogenous proteins delivered by adenoviral transduction was 
verified (Chapter 3, Figure 8 A). Erg over-expression led to a 10-fold decrease of 
ICAM-1 basal levels (Chapter 3, Figure 8 B). This result confirms that the functional 
effect on ICAM-1 levels exerted by Erg over-expression is not restricted to HUVEC, 
suggesting that it could be relevant to other venous and arterial endothelial cells. 
 
 
     
Chapter 3, Figure 8. ICAM-1 protein levels are decreased by Erg over-expression in 
resting HCAEC. Virus-encoded proteins detected by western blot in HCAEC (A) 
with an antibody to V5. ICAM-1 total protein levels from HCAEC (B) were 
normalized to GAPDH and shown as fold change over AdLacZ transduction. n=3. 
*P<0.05; **P<0.01; ***P<0.001 
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3.1.2.3 Regulation of ICAM-1 transcriptional activity in Erg over-
expressing cells 
Because Erg inhibition leads to an increase of ICAM-1 promoter activity (Chapter 3, 
Figure 4) we hypothesized that Erg over-expression would lead to ICAM-1 
transcriptional repression of the ICAM-1 gene. To test this, ICAM-1 promoter 
activity was measured in HUVEC over-expressing Erg. HUVEC were transduced 
with either AdLacZ or AdErg for 24 hours, then transfected for 24 hours with either 
ICAM-1 promoter luciferase reporter, or the empty vector luciferase construct 
(pGL4) as negative control. As shown in Chapter 3, Figure 9, ICAM-1 promoter 
activity was repressed by Erg over-expression. This result confirms that Erg inhibits 
ICAM-1 at the transcriptional level.  
 
Chapter 3, Figure 9.  ICAM-1 promoter activity is decreased by Erg over-expression 
in resting HUVEC (experiment carried out by Nicky Dryden). AdErg or AdLacZ 
transduced HUVEC were transfected with ICAM-1 promoter luciferase reporter 
plasmid for 24 hours. Values are relative to pGL4-AdLacZ control. n=3. *P<0.05; 
**P<0.01 
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3.1.3 Erg over-expression inhibits TNF-α-mediated up-regulation 
of pro-inflammatory molecules 
3.1.3.1 Analysis of Erg, ICAM-1, IL-8 and VCAM-1 mRNA levels 
after Erg over-expression in TNF-α stimulated HUVEC 
Since Erg downregulation leads to an increase of basal ICAM-1 levels (paragraph 
3.1.1), and Erg over-expression represses basal ICAM-1 levels (paragraph 3.1.2), the 
question of whether Erg could also repress the TNF-α-induction of ICAM-1 was 
addressed. To test this hypothesis, Erg was over-expressed in TNF-α-treated cells. 
HUVEC transduced with either AdErg or AdLacZ were treated with TNF-α for 24 
hours. Erg over-expression led to a 50 fold increase in Erg mRNA levels (Chapter 3, 
Figure 10 A), and significantly inhibited TNF-α-induced mRNA up-regulation of 
ICAM-1, VCAM-1 and IL-8 (Chapter 3, Figure 10 B). These data indicate that Erg 
plays a role in repressing cytokine-induced pro-inflammatory gene expression in EC. 
Because the genes found to be repressed by Erg are transcriptional targets of NF-kB, 
these data also point to a role for Erg in repressing the NF-kB pathway.  
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Chapter 3, Figure 10. Pro-inflammatory gene expression is repressed by Erg over-
expression in TNF-α-stimulated HUVEC. Cells were transduced with either AdLacZ 
or AdErg for 24 hours, and then treated with TNF-α (10 ng/ml) for 24 hours. Erg 
(A), ICAM-1, VCAM-1 and IL-8 (B) mRNA levels were quantified using RT-PCR, 
and normalized to GAPDH.  
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3.1.3.2 Analysis of ICAM-1 protein levels after Erg over-expression 
in TNF-α stimulated HUVEC 
To confirm that Erg represses the TNF-α-induced ICAM-1 expression in EC, either 
AdLacZ or AdErg were used to transduce EC for 48 hours. To investigate the Erg 
mediated repression on ICAM-1 in HUVEC, TNF-α (10 ng/ml) was added to the cell 
culture media for the last 24 hours of incubation, before analysing cell lysates by 
western blot. The expression of the exogenous V5-tagged proteins was confirmed 
(Chapter 3, Figure 11 A). As expected, TNF-α stimulation dramatically increased 
ICAM-1 protein expression. TNF-α-induced ICAM-1 protein levels were reduced by 
Erg over-expression (Chapter 3, Figure 11 B). Interestingly, AdErg inhibited TNF-α-
induced up-regulation of ICAM-1 in a dose-dependent way in HUVEC (Chapter 3, 
Figure 11 B, C). Among the 2 receptors binding TNF-α on EC (TNFR1 and TNFR2), 
TNFR1 is the most important, being the isoform that preferentially binds the soluble 
form of TNF-α, and because is the main receptor mediating TNF-α-dependent 
induction of ICAM-1.
26;97
 Expression of TNFR1  was not downregulated by Erg 
over-expression (Chapter 3, Figure 11 D). Therefore Erg inhibits TNF-α-dependent 
up-regulation of ICAM-1 protein by affecting signaling pathways downstream of its 
receptor. A major pro-inflammatory pathway downstream to TNFR1 is NF-kB. 
Because Erg seems to be involved in regulating basal ICAM-1 levels via NF-kB (see 
paragraph 3.1.1.5) and Erg represses the TNF-α  induction of NF-kB target genes, we 
decided to focus on this pathway. The results related to this topic are shown in 
paragraph 3.1.4.   
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Chapter 3, Figure 11. ICAM-1 protein levels are decreased by Erg over-expression in 
TNF-α-stimulated HUVEC. HUVEC were transduced with AdLacZ or AdErg for 24 
hours, and then stimulated with TNF-α for a further 24 hours. Virus-encoded proteins 
detected by western blot (A) with an antibody to V5. ICAM-1 total protein levels 
were normalized to GAPDH and shown as fold change over AdLacZ transduction. C, 
ICAM-1 protein levels from HUVEC transduced with a lower dose of adenovirus 
(MOI: 10). D, TNFR1 protein levels from HUVEC transduced with AdLacZ and 
AdErg and stimulated with TNF-α. n=3. *P<0.05; **P<0.01; ***P<0.001 
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3.1.3.3 Analysis of ICAM-1 protein levels after Erg over-expression 
in TNF-α stimulated HCAEC 
To test whether the effect of Erg over-expression on TNF-α-induced ICAM-1 protein 
levels was specific to HUVEC, ICAM-1 protein levels were also measured in 
HCAEC following stimulation with TNF-α (10 ng/ml) for 24 hours. The expression 
of the exogenous proteins transduced by adenovirus was verified by western blot 
(Chapter 3, Figure 12 A). Erg over-expression led to a 30-fold decrease of TNF-α-
induced ICAM-1 levels (Chapter 3, Figure 12 B). This result confirms that the 
functional effect on TNF-α-induced ICAM-1 levels exerted by Erg over-expression 
is not restricted to HUVEC, since Erg represses TNF-α-induced ICAM-1 expression 
in EC derived from an arterial endothelial bed. 
 
 
 
Chapter 3, Figure 12. ICAM-1 protein levels are decreased by Erg over-expression in 
TNF-α-stimulated HCAEC. HCAEC were transduced with AdLacZ or AdErg for 24 
hours, and then stimulated with TNF-α for a further 24 hours. A, virus-encoded 
proteins detected by western blot with an antibody to V5. B, ICAM-1 total protein 
levels were normalized to GAPDH and shown as fold change over AdLacZ 
transduction. 
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3.1.3.4 Analysis of ICAM-1 promoter activity after Erg over-
expression in TNF-α stimulated HUVEC 
In order to promote ICAM-1 transcription, different pro-inflammatory signalling 
pathways converge to specific transcription factor binding sites on the ICAM-1 
promoter. So far, the main pro-inflammatory pathways activated by TNF-α are AP1, 
p38 MAPK and NF-kB.
24
 Both AP1 and NF-kB functional binding sites have been 
identified on the ICAM-1 promoter (
78
 and Chapter 1, Figure 4). To investigate 
whether the Erg-dependent repression of TNF-α-induced ICAM-1 was 
transcriptional, we made use of the ICAM-1 luciferase reporter in Erg over-
expressing EC. HUVEC were transduced with AdErg or AdLacZ for 24 hours, and 
stimulated with TNF-α (10ng/ml) for the last 6 hours of incubation. As expected, 
TNF-α stimulation transactivated the ICAM-1 promoter. Interestingly, TNF-α-
induced ICAM-1 promoter activity was inhibited by Erg over-expression (Chapter 3, 
Figure 13). This result shows that Erg represses TNF-α-induced ICAM-1 promoter 
activity, and led us to investigate the role for Erg in repressing the NF-kB pathway 
(see next paragraph, 3.1.4), since Erg has previously been proposed to repress the 
constitutive ICAM-1 expression by repressing NF-kB (paragraph 3.1.1.5).  
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Chapter 3, Figure 13. ICAM-1 promoter activity is decreased by Erg over-expression 
in TNF-α stimulated HUVEC (experiment carried out by Nicky Dryden). AdErg or 
AdLacZ transduced HUVEC were transfected with ICAM-1 promoter luciferase 
reporter plasmid for 24 hours and treated with TNF-α for 6 hours. Values are relative 
to pGL4-AdLacZ control. n=3. *P<0.05; **P<0.01 
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3.1.4 Erg over-expression inhibits NF-kB 
3.1.4.1 Analysis of NF-kB activity after Erg over-expression: 
optimization experiments 
Because Erg over-expression inhibits TNF-α induction of the NF-kB target genes 
ICAM-1, VCAM-1 and IL-8 (see paragraph 3.2.3), and that Erg represses TNF-α 
induction of ICAM-1 at the transcriptional level (Chapter 3, Figure 13), we 
hypothesized that Erg could repress the TNF-α induction of the NF-kB pathway. To 
investigate this, a NF-kB luciferase reporter plasmid was used, as previously 
described,
214
 and used to perform control experiments. The 3' of the synthethic NF-
kB luciferase reporter was sequenced, and 4 potential NF-kB binding sites were 
identified by computational analysis (Chapter 3, Figure 14 A). Among these 4 
binding sites, 2 were previously reported to be functionally active NF-kB-responsive 
sites on the VCAM-1 promoter.
224
 To assess the effects of Erg on NF-kB activity, a 
test experiment was carried out. Hela cells were  transfected with the NF-kB 
luciferase reporter plasmid and with either an Erg encoding plasmid or a control 
plasmid for 24 hours, and then treated with TNF-α (10 ng/ml) or left untreated for 16 
hours. Erg over-expression resulted in a minor decrease of NF-kB activity (Chapter 
3, Figure 14 B). However, in this experiment the expression levels of Renilla 
Luciferase (Rluc/TK, plasmid used to normalize for transfection efficiency, see 
Methods for details) were altered by the combination of Erg over-expression and 
TNF-α stimulation, resulting in an unclear readout (data not shown). Thus a different 
experimental design was adopted (see next paragraph). 
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Chapter 3, Figure 14. Erg inhibits NF-kB activity: optimization experiments. A, 
sequence of the 3’ NF-kB responsive region of the NF-kB luciferase reporter. ETS 
consensus sequences (bold), potential NF-kB binding sites identified by 
Matinspector analysis (boxed), NF-kB responsive sequences present on the VCAM-1 
promoter
224
 (red), potential ETS binding sites identified by Matinspector analysis 
(underlined), and the primer sequence (arrow; NF-kB R, table 2) are shown. B, Hela 
cells were transfected with a NF-kB luciferase reporter plasmid and with an Erg 
encoding plasmid or control plasmid for 24 hours, then treated with TNF-α (10 
ng/ml) or left untreated for 16 hours. n=1.  
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3.1.4.1 Analysis of basal and TNF-α-induced NF-kB activity after 
Erg over-expression in EC 
In order to assess with high specificity and sensitivity if Erg repressed NF-kB 
activity, the experimental setting reported in the previous paragraph was improved. 
Because luciferase experiments were successfully performed in the past in our lab 
adopting HUVEC,
180
 these cells were transduced with AdErg or AdLacZ, in order to 
maintain the conditions of Erg-mediated pro-inflammatory gene repression (see 
paragraph 3.1.2 and 3.1.3) unchanged. HUVEC were then transfected with the NF-
kB luciferase reporter, and treated with TNF-α (10 ng/ml) for 6 hours, in order to 
minimize any eventual secondary effects due to longer stimulation with TNF-α. 
Moreover, in all the conditions used for this experiment the expression levels of 
Renilla Luciferase resulted unchanged (data not shown), allowing a proper 
normalization of the data analyzed. As expected, TNF-α stimulation transactivated 
the NF-kB reporter. Erg over-expression significantly inhibited TNF-α dependent 
NF-kB-driven reporter activity, compared to AdLacZ-transduced and non transduced 
cells (Chapter 3, Figure 15, dark grey bars). This result confirms that Erg represses 
the TNF-α-mediated induction of the NF-kB pathway.   Moreover, for the purpose of 
this thesis, this data is more relevant than the one shown in Chapter 3, Figure 14 B, 
since EC were used instead of Hela, and because cells were transduced with the same 
vectors (AdErg and AdLacZ) used in all the other over-expression experiments 
shown here.   
Interestingly, Erg-over-expression also repressed basal NF-kB reporter activity 
(Chapter 3, Figure 15, light grey bars). This further supports the data shown in 
paragraph 3.1.1.5, where Erg repression of the constitutive pro-inflammatory NF-kB 
signaling cascade was investigated. Although at low levels, NF-kB p65 is expressed 
 113 
in the nucleus of resting EC in vivo,
124;220
 and p65 deficient cells show decreased 
levels of ICAM-1 in vitro.
222
 Therefore, this data indicates that the Erg mediated 
repression of basal pro-inflammatory gene expression involves NF-kB.  
 
 
 
 
 
 
 
 
Chapter 3, Figure 15. Erg inhibits basal and TNF-α-induced NF-kB activity in EC. 
AdErg- or AdLacZ-transduced HUVEC were transfected with a NF-kB luciferase 
reporter plasmid for 48 hours, then treated with TNF-α (10 ng/ml) or left untreated 
for the final 6 hours. Values are relative to pGL2. n=3. *P<0.05 
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3.1.4.2 Analysis of IkBα levels over a time-course of TNF-α-
stimulation after Erg over-expression 
NF-kB activation is tightly controlled at different levels. In quiescent cells, IkBα 
binds and retains NF-kB dimers in the cytoplasm. Following pro-inflammatory 
stimuli, degradation of IkBα releases NF-kB which translocates into the nucleus to 
bind DNA.
44
 Because IkBα protein has been shown to be stabilized by proteins 
repressing TNF-α-induced NF-kB activity,214 we investigated whether Erg could 
repress TNF-α-induced IkBα degradation. Western blots on total cell lysates from 
either AdLacZ or AdErg transduced HUVEC stimulated with TNF-α revealed that 
IkBα was entirely degraded between 15 and 30 minutes of TNF-α treatment (Chapter 
3, Figure 16 A, B), indicating that Erg does not prevent the TNF-α-induced  IkBα 
degradation. Accordingly to the normal IkBα turnover previously reported in TNF-α 
stimulated HUVEC,
97
 the recovery of IkBα levels was not complete 2 hours after 
TNF-α stimulation in cells transduced with control virus (Chapter 3, Figure 16 A). 
Interestingly, IkBα re-synthesis was quicker in Erg over-expressing cells, reaching 
basal levels of expression after 2 hours of TNF-α stimulation (Chapter 3, Figure 16 
B). These data indicate that Erg could repress the TNF-α-induced NF-kB activity by 
increasing the IkBα post-degradation recovery, therefore enhancing the quenching of 
NF-kB activation.  
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Chapter 3, Figure 16. Erg induces the expression of the NF-kB inhibitor IkBα 
following TNF-α stimulation. Time course of AdLacZ (A) and AdErg (B) transduced 
HUVEC, treated with TNF-α (10ng/ml) for the indicated period of time. IkBα 
expression is quantified relative to GAPDH and normalized against either AdLacZ- 
or AdErg-transduced HUVEC at T0. 
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3.1.4.3 Analysis of NF-kB expression and TNF-α-induced nuclear 
translocation after Erg over-expression 
Because Erg does not stabilize IkBα from being degraded after TNF-α stimulation, 
NF-kB translocation into the nucleus is not likely to be impaired by Erg in these 
conditions. To confirm this hypothesis we measured the extent of NF-kB p50/p65 
translocation into the nucleus in TNF-α stimulated cells over-expressing Erg. 
AdLacZ or AdErg transduced HUVEC were treated with TNF-α (10 ng/ml) for 30 
minutes (when the maximum level of NF-kB nuclear translocation occurs),
225
 and 
then processed for cytosolic/nuclear fractionation. The purity of the cytosolic 
fractions was confirmed by western blot using antibodies to α-tubulin and NF-kB 
p105, whereas the nuclear protein HDAC-1 was selectively expressed in the nuclear 
fractions. V5-tagged Erg protein was only detected in the nucleus of both resting and 
TNF-α stimulated cells, showing the same localization pattern of the endogenous Erg 
protein.
179
 Both p50 and p65 translocated to  similar extent into the nucleus of TNF-
α-stimulated cells over-expressing Erg or β-galactosidase (Chapter 3, Figure 17 A). 
To exclude the possibility that Erg could affect NF-kB expression levels in resting 
cells, total cell lysates from either AdLacZ or AdErg transduced HUVEC were 
analysed for p50 and p65 expression. The expression levels of these 2 proteins were 
unchanged (Chapter 3, Figure 17 B). These results are in line with the data shown in 
the previous paragraph (3.1.4.2), therefore Erg does not repress the TNF-α-induced 
NF-kB activity by interfering with NF-kB translocation.   
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Chapter 3, Figure 17. Erg over-expression does not affect total levels and nuclear 
translocation of p65:p50 following TNF-α treatment. A, left panel: cytoplasmic (C) 
and nuclear (N) fractions from HUVEC stimulated with TNF-α for 30 minutes or left 
unstimulated, transduced with AdLacZ or AdErg, were analysed by western blot 
using antibodies to V5, p65 and p50. α-tubulin (cytoplasmic loading control) and 
NF-kB p105 (precursor to p50, only expressed in the cytosol) are shown to 
demonstrate the purity of the cytosolic fractions. A, right panel: Values for the 
nuclear fractions for p65 (top) and p50 (bottom) are normalized to HDAC-1 and 
shown as fold change over AdLacZ-transduced cells with TNF-α. B, Erg over-
expression does not affect p65 or p50 total protein levels. Total protein levels from 
AdLacZ- or AdErg-transduced HUVEC treated with TNF-α for 24 hours were 
analysed. Protein expression was normalized to GAPDH and quantified relative to 
AdLacZ control. n=3. 
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3.1.4.4 Analysis of the TNF-α-induced binding of NF-kB p65 to the 
ICAM-1 promoter after Erg over-expression 
After translocating into the nucleus, p65 exerts its transcriptional activity by binding 
to specific NF-kB consensus sequences on target genes and recruiting the 
transcriptional machinery.
142
 The ICAM-1 promoter contains 2 NF-kB functional 
binding sites.
78
 Among these 2, the NF-kB binding site proximal to the ICAM-1 
transcription starting site, which flanks an ETS site (Chapter 1, Figure 4), has been 
shown to be responsive to TNF-α stimulation.96 Because Erg binds to a region of the 
ICAM-1 promoter which includes the flanking NF-kB-ETS site (
181
, Chapter 1, 
Figure 4), we hypothesized that Erg could repress p65 transcriptional activity by 
displacing p65 from its transcription binding site. To investigate this, p65 binding to 
this region was assessed in vitro using an ELISA based assay. Nuclear lysates from 
TNF-α stimulated HUVEC transduced with either AdLacZ or AdErg were incubated 
with biotinilated oligonucleotides corresponding to the ICAM-1 promoter sequence 
which includes the NF-kB-ETS flanking site, and the binding of p65 to this sequence 
was measured by ELISA. Binding of p65 to its target sequence, which was below the 
threshold of detection, was significantly induced by TNF-α treatment. TNF-α-
induced p65 binding was not repressed by Erg over-expression (Chapter 3, Figure 
18), indicating that Erg might repress the p65-induced transactivation of the ICAM-1 
promoter by interfering with events downstream to p65 nuclear translocation and 
DNA binding. 
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Chapter 3, Figure 18. Erg over-expression does not affect p65 binding to the TNF-α-
inducible binding site on the ICAM-1 promoter. Nuclear extracts from either 
AdLacZ- or AdErg-transduced HUVEC stimulated with TNF-α (or not stimulated) 
were mixed with a biotin labelled oligonucleotide containing the proximal NF-kB 
p65 binding site of the ICAM-1 promoter (ICAM-1 biotin-F, see Table 2). p65 
binding was quantified by ELISA and normalized against AdLacZ-transduced cells. 
*P<0.05; **P<0.01  
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3.1.4.5 Analysis of the TNF-α-induced phosphorylation of NF-kB 
p65 in Erg over-expressing cells 
P65 transcriptional activity is tightly controlled by post-translational modifications, 
including phosporylation, acetylation, ubiquitination, nitration and proline 
isomerisation (Chapter 1, Figure 7).
136
 Among these modifications, phosphorylation 
of specific residues within the p65 transactivation domains has been reported as a 
key event in the regulation of p65 function.
151
 TNF-α stimulation induces p65 
phosphorylation at different residues with distinct and sometimes antagonistic effects 
on p65 transcriptional regulation.
159;160;162;226
 Among these modifications, TNF-α-
induced phosphorilation of p65 at S536 enhances NF-kB transcriptional activity
165
 
and has been shown to induce the transactivation of the NF-kB target gene IL-8.
159
 A 
microarray study performed in our lab on HUVEC treated with Erg or ctl GB for 48 
hours (see paragraph 3.1.1, Birdsey G. and Randi A.M., submitted to Blood) revealed 
a potential role for Erg in repressing the expression of IKKβ and TBK1, two kinases 
involved in the phosphorylation of p65 at S536 (see next paragraph, and 
159;162
). 
Therefore, we hypothesized that Erg could repress p65 phosphorylation at this 
specific residue. To test this, nuclear and cytoplasmic lysates from HUVEC 
transduced with AdLacZ or AdErg and stimulated with TNF-α (10 ng/ml) for 30 
minutes were obtained. They were analysed by western-blot with antibodies 
selectively recognizing the phosphorylated form of p65 at S536. According to 
previous studies, basal p65 phosphorylation was low, and was markedly increased in 
the cytoplasm of cells stimulated with TNF-α (162; Chapter 3, Figure 19). 
Interestingly, Erg over-expression led to a 2-fold repression of p65 phosphorylation 
both in the cytoplasm and in the nucleus of TNF-α stimulated cells. This result, in 
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line with the data shown in Chapter 3, Figure 14 B, suggests a new role for Erg in 
repressing TNF-α-induced NF-kB activation. 
 
 
 
 
 
Chapter 3, Figure 19. Erg over-expression represses the TNF-α-induced 
phosphorylation of NF-kB p65. cytoplasmic (C) and nuclear (N) fractions from 
HUVEC transduced with AdLacZ or AdErg, and stimulated with TNF-α for 30 
minutes or left unstimulated, were analysed by western blot using antibodies to 
phospho-p65 (Ser536) and total p65. Values for phospho-p65 are normalized to total 
p65 and represented as fold change over nuclear fractions from AdLacZ-transduced 
cells treated with TNF-α. n=3 to 4. *P<0.05; **P<0.01  
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3.1.4.6 Analysis of the Erg-mediated regulation of protein kinases 
invoved in p65 phosphorylation at Ser 536 
As mentioned in the previous paragraph, IKKβ and TBK1 were highlighted as 
molecules repressed by Erg in a microarray study performed on HUVEC. To validate 
the microarray data, Erg expression was either downregulated by Genebloc or 
upregulated by adenoviral transduction, and IKKβ and TBK1 mRNA levels were 
measured. 
Both IKKβ and TBK1 levels were increased following 48 hours of Erg 
downregulation, confirming the result obtained from the microarray analysis and 
suggesting a potential role for Erg in repressing their expression. Erg over-expression 
led to a small but significant decrease of IKKβ mRNA levels, while TBK1 levels 
remained unchanged (Chapter 3, Figure 20 B, D). Therefore these data strongly 
suggest that IKKβ mRNA is a target of Erg repression, whilst the results for TBK1 
are inconclusive. Although there is no evident explanation for this controversy, these 
data may indicate that Erg is necessary but not sufficient to repress TBK1 levels, and 
that some other mechanisms play a role independently of Erg. Erg could therefore 
play a role in repressing TBK1, but it is unlikely that the Erg mediated effects on p65 
phosphorylation identified in this study (see paragraph 3.1.4.5) are due to TBK1 
expression levels, since those results were obtained in a model of Erg over-
expression. 
To furher investigate whether IKKβ protein was repressed by Erg, IKKβ protein 
levels were analysed in HUVEC where Erg was either inhibited with Genebloc or 
over-expressed with adenovirus. Neither of these 2 treatments led to a change in  
IKKβ protein levels (Chapter 3, Figure 21). This result indicates that IKKβ protein 
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levels do not reflect the subtle changes detected by analysing IKKβ mRNA in the 
same experimental conditions. This might be due to the same time point chosen for 
the analysis in the two experiments. 
Overall, the finding that Erg over-expression does not repress the expression levels 
of IKKβ and TBK1 suggests that a different mechanism, eventually regulating these 
kinases' activity, could be governed by Erg to regulate p65 phosphorylation at S536.  
 
 
Chapter 3, Figure 20. Erg regulation of IKKβ and TBK1 mRNA levels. HUVEC 
were transfected with either Erg or ctl GB. mRNA levels for Erg (A) and TBK-1 (C) 
were measured after 48 hours, and normalized to GAPDH. HUVEC were transduced 
with either AdLacZ or AdErg for 48 hours. IKKβ (B) and TBK1 (D) mRNA levels 
were quantified using RT-PCR, and normalized to GAPDH. n=3. *P<0.05; 
**P<0.01 
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Chapter 3, Figure 21. IKKβ protein levels are not regulated by Erg. A, HUVEC were 
transfected with either Erg or ctl GB. B, HUVEC were transduced with either 
AdLacZ or AdErg for 48 hours. IKKβ protein levels were measured after 48 hours, 
and normalized to GAPDH. n=3. 
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3.2 Erg as a repressor of inflammation. Functional studies in 
vitro and in vivo 
 
3.2.1 Erg regulates leukocyte adhesion in vitro 
The in vitro data described so far pointed to a role for Erg as a transcriptional 
repressor of inflammation. Previously Erg was shown to inhibit leukocyte adhesion 
to unstimulated HUVEC.
182
 To test whether Erg may also repress TNF-α-induction 
of leukocyte adhesion to EC, leukocyte adhesion on TNF-α-stimulated HUVEC was 
studied using a well-characterized assay dependent on multiple factors, including 
ICAM-1 and IL-8.
227
 Labelled HL60 cells, which express the ICAM-1 counter 
receptor LFA-1, were incubated with HUVEC transduced with AdErg or AdLacZ for 
48 hours and activated with TNF-α (10 ng/ml) for 24 hours. Erg over-expression 
significantly inhibited HL60 binding to TNF-α-activated HUVEC (Chapter 3, Figure 
22), confirming that the inhibition of TNF-α signalling by Erg is functionally 
relevant.  
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Chapter 3, Figure 22. Erg over-expression results in decrease of TNF-α-induced 
leukocyte adhesion to the endothelium in vitro. AdLacZ- or AdErg-transduced 
HUVEC were activated with TNF-α (10 ng/ml) for 24 hours. Labelled HL60 cells 
were incubated with transduced HUVEC at 37 C° for 30 minutes. Adherent cells 
were lysed and total fluorescence was measured. Leukocyte binding was quantified 
relative to unstimulated AdLacZ-transduced HUVEC. n=3. *P<0.05.  
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3.2.2 Erg regulates inflammation in vivo 
3.2.2.1 Characterization of TNF-α-induced paw swelling mouse 
model 
Since Erg has a functional role in repressing the TNF-α-induced expression of 
adhesion molecules (see paragraph 3.1) and leukocyte adhesion in vitro (paragraph 
3.2.1), we hypothesized that Erg over-expression could also prevent inflammation in 
vivo, and particularly the TNF-α-induction of paw swelling. To test this, we used a 
mouse model of inflammation induced by injection of TNF-α in the paw.228 First we 
validated the relevance of leukocyte recruitment and induction of ICAM-1 levels in 
this mouse model. To study this, mice received a sub-cutaneous injection of either 
PBS or murine TNF-α (50 ng/10 ul) into the footpad of right paw and paw swelling 
was monitored over-time. Paw swelling was acutely induced by TNF-α but not PBS 
injection (Chapter 3, Figure 23 A, B, C), and this effect was partially inhibited by 
pre-injection of the paw with ICAM-1 blocking antibodies (Chapter 3, Figure 23 A), 
indicating that ICAM-1 plays a role in inducing TNF-α-induced paw swelling. To 
confirm the role for ICAM-1 and leukocyte recruitment in this model of 
inflammation, sections from paws 2 hours after injection with PBS or TNF-α were 
stained with antibodies to ICAM-1 and the leukocyte marker myeloperoxidase 
(MPO), respectively. Serial sections were also stained with H&E. As shown in 
Chapter 3, Figure 23 D, TNF-α injection led to an increase of both ICAM-1 
expression and leukocyte transmigration into the inflamed area. These results show 
that TNF-α injection in the mouse footpad leads to an ICAM-1 dependent induction 
of leukocyte transmigration and oedema.  
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Chapter 3, Figure 23. Characterisation of the TNF-α-induced paw swelling model of 
inflammation (experiment carried out by Leigh Madden). A, ICAM-1 is involved in 
mediating TNF-α-induced paw swelling. Mice were injected with anti-ICAM-1 or 
IgG antibodies for 24 hours, then injected with TNF-α. Paw thickness was measured 
over-time. B-C, PBS injection has no effect on paw swelling. B: Mice were injected 
with AdErg or AdLacZ and then with TNF-α. Non-infected animals were injected 
with either PBS or TNF-α. C, mice were injected with either TNF-α alone or PBS in 
addition to TNF-α, and paw swelling was measured at the indicated time-points. 
Mice previously injected with AdErg or AdLacZ are also shown. D, Mice treated as 
in B were assessed for leukocyte infiltration in the paw by H&E and MPO staining, 
and for ICAM-1 expression. Both ICAM-1 expression (arrows) and neutrophil 
infiltration (dotted arrows) were induced by TNF-α. Neg., isotype control. Scale bars 
= 200 μm. 10x objective. n=5; *P<0.05; **P<0.01; ***P<0.001.  
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3.2.2.2 Detection of AdErg transduction in vivo  
To investigate whether Erg has an anti-inflammatory role in vivo, we over-expressed 
Erg by injecting AdErg into the mouse footpad 24 hours prior to TNF-α injection. 
Mice injected with AdLacZ were used as negative controls. 
To verify that the Erg transgene was effectively transduced by AdErg in vivo, Erg 
expression in the paw was analysed by IHC and RT-PCR. Erg staining was 
predominantly restricted to EC of both AdErg and AdLacZ injected animals, as 
expected, but no clear difference between these 2 conditions was observed (Chapter 
3, Figure 24A). This might be due to poor sensitivity of this specific technique. 
Therefore a different approach was adopted to verify the Erg over-expression in 
AdErg injected animals. Using primers spanning the exogenous Erg-V5 tag, semi-
quantitative mRNA analysis revealed the expression of the exogenously encoded Erg 
construct selectively in the paws injected with AdErg (Chapter 3, Figure 24B). 
Therefore the expression of the Erg construct was confirmed in vivo. To further 
support this finding, total cell lysates from transduced paws were 
immunoprecipitated with anti-V5 antibodies and processed for SDS-PAGE with 
antibodies against V5 and Erg, in order to detect the expression of the exogenous Erg 
protein using a biochemical approach. As positive control, HUVEC were transduced 
for 48 hours with AdLacZ, and V5-βGal was successfully detected by WB (Chapter 
3, Figure 25, Chapter 3, Figure 26 A) and immunoprecipitation (Chapter 3, Figure 26 
A). However, these antibodies failed to detect the exogenous proteins expressed in 
the paw samples. The anti-V5 antibody recognized a similar, possibly aspecific, 
pattern of bands in all the transduced paw samples but not in HUVEC, ranging 
between 55 and 70 kDa (Chapter 3, Figure 25, top panel), whereas both the anti-V5 
and anti-Erg antibodies did not detect any Erg bands by Western-Blot following 
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immunoprecipitation with antibodies against V5 (Chapter 3, Figure 25, Chapter 3, 
Figure 26). This suggests that the transduction efficiency of AdLacZ and AdErg in 
vivo is not high, possibly due to the high amount and heterogeneity of cells in a tissue 
if compared to an in vitro experiment performed on a homogeneous cell population 
(eg. HUVEC, see Chapter 3, Figure 11 A). Nonetheless, AdErg transduction in the 
paw has a functional effect and is detectable by RT-PCR (Chapter 3, Figure 24 B).        
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Chapter 3, Figure 24. Erg expression in mice injected with AdErg. A, serial paw 
sections from AdErg or AdLacZ-injected mice were stained with H&E or with 
antibodies against CD31 (as EC marker) or Erg. Erg staining is most intense in 
endothelial cells lining the vessels (arrows). Insert: IgG negative controls. Scale bars 
= 100 μm. 20x objective. (Experiment carried out by Leigh Madden). B, semi-
quantitative RT-PCR analysis showing the presence of V5-Erg mRNA selectively in 
the footpad of AdErg injected mice. GAPDH band shows the presence of similar 
amounts of starting material in all the samples. n=5.  
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Chapter 3, Figure 25. Analysis of total cell lysates from mouse footpads transduced 
with AdErg and AdLacZ. Paws were injected with AdErg or AdLacZ for 24 hours 
and with TNF-α for a further 24 hours. Total cell lysates were obtained, processed 
for SDS-page and analysed with antibodies against V5 (top panel) and Erg (bottom 
panel). 
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Chapter 3, Figure 26. Analysis of immunoprecipitated lysates from mouse footpads 
transduced with AdErg and AdLacZ. Paws were injected with AdErg or AdLacZ for 
24 hours and with TNF-α for a further 24 hours. HUVEC were transduced for 48 
hours with AdLacZ. Total cell lysates were obtained, and equal amounts (500 µg) 
were immunoprecipitated (IP) with antibodies against V5 or with IgG isotype 
controls, processed for SDS-page and analysed with antibodies against V5 (A) and 
Erg (B). 
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3.2.2.3 Erg regulation of TNF-α-induced paw swelling  
Having shown that the exogenous Erg transgene was expressed in vivo following 
adenoviral delivery (see previous paragraph), the functional effects of Erg over-
expression on inflammation were assessed in the paw swelling mouse model 
previously characterized (paragraph 3.2.2.1). Erg was over-expressed by adenovirus 
(AdErg) injection into the mouse footpad 24 hours prior to TNF-α injection. As 
negative control, paw swelling was measured in mice injected with the same dose of 
AdLacZ. TNF-α-induced paw swelling was significantly reduced in mice injected 
with AdErg compared to control animals (Chapter 3, Figure 27 A. See also Chapter 
3, Figure 23 C), and repression of inflammation was lost with a lower titer of AdErg, 
suggesting a dose-dependent effect (Chapter 3, Figure 27 B). Staining of paw 
sections around the area of injection  showed reduced ICAM-1-positive vascular 
structures in AdErg-treated mice compared to control, as well as reduced 
inflammatory infiltrate (shown both by H&E and MPO staining) (Chapter 3, Figure 
27 C). These results indicate that Erg can inhibit TNF-α-induced acute inflammation 
in vivo. 
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Chapter 3, Figure 27. Erg over-expression inhibits paw swelling, leukocyte 
recruitment and ICAM-1 expression in a TNF-α-dependent mouse model of 
inflammation (Experiment carried out by Leigh Madden). Mice received a single 
intraplantar injection of either AdLacZ or AdErg at a concentration of either 10
7
 (A) 
or 10
6
 (B) PFU, and 24 hours later were injected with TNF-α in the same location; 
paw thickness was measured at the indicated time-points (see Methods for details). 
C, 2 hours after TNF-α injection, tissue samples from the injected paws were 
assessed for ICAM-1 expression, and for leukocyte infiltration by H&E and MPO 
staining. Both ICAM-1 expression (arrows) and MPO staining, which denotes 
neutrophil infiltration (dotted arrows), were reduced by AdErg. Neg.: isotype control. 
Scale bars = 200 μm. 10x objective. n=5.  ***P<0.001.   
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3.3 Regulation of Erg expression during inflammation 
The Erg protein is down-regulated by pro-inflammatory molecules in vitro and in 
vivo: McLaughlin et al. showed for the first time that Erg can be downregulated by 
TNF-α in EC.180 A recent study from Yuan et al. confirmed this finding and showed 
that Erg can also be downregulated in vivo by LPS and in a mouse model of sepsis.
182
 
Because Erg has a functional role in repressing inflammation,
181
 the understanding of 
how Erg expression is down-regulated could represent a potential step towards 
validating Erg as a target for a therapeutic intervention. For this reason we 
investigated the mechanisms of TNF-α mediated Erg downregulation in HUVEC. 
Furthermore, since TNF-α plays a role in the pathogenesis of chronic inflammatory 
diseases such as atherosclerosis (discussed in paragraph 1.1.1), we analysed the Erg 
expression profile on the endothelium overlaying eccentric human atherosclerotic 
plaques, in order to understand if Erg expression is also regulated during human 
chronic inflammation. 
3.3.1 Erg expression is regulated by TNF-α in vitro 
3.3.1.1 Analysis of Erg protein levels in TNF-α stimulated cells 
To start investigating the mechanisms regulating the Erg downregulation by TNF-α, 
HUVEC were treated with TNF-α (10ng/ml) over a time course and processed for 
western blotting with antibodies to Erg. To control for the functional activity of 
TNF-α, the same samples were processed for ICAM-1 protein analysis. As expected, 
ICAM-1 levels were significantly induced by TNF-α stimulation. Erg was 
downregulated by  TNF-α over-time, reaching 50% of the initial levels after 10 hours 
of TNF-α stimulation. Unexpectedly, Erg levels were completely recovered after 24 
hour of TNF-α stimulation (Chapter 3, Figure 28 A). This is not in agreement with 
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what shown by 2 previous works,
180;182
 but is in line with the Erg mRNA expression 
profile shown in the next paragraph (3.3.1.2). 
 
 
 
 
Chapter 3, Figure 28. Erg protein is downregulated over-time by TNF-α. HUVEC 
were treated with TNFα (10 ng/ml). Cells were lysed after the indicated time points 
and 20 μg of the cell lysate were analysed. Proteins were separated by SDS-PAGE 
and probed with polyclonal anti-Erg (A), monoclonal anti-ICAM-1 (B) and anti-
GAPDH antibodies (A, B). Erg and ICAM-1 protein expression is quantified relative 
to GAPDH and normalized against untreated HUVEC (A), or HUVEC treated with 
TNF-α for 2 hours (B). n=3, *P<0.05; **P<0.01. 
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3.3.1.2 Analysis of Erg mRNA levels in TNF-α stimulated cells 
Protein downregulation can be either the consequence of decreased gene 
transcription, decreased mRNA/protein stability, or increased protein degradation. To 
investigate if TNF-α stimulation inhibited Erg mRNA expression, HUVEC were 
treated with TNF-α (10ng/ml) over a time course and processed for RT-PCR. 
Interestingly, Erg mRNA was not downregulated by TNF-α stimulation (Chapter 3, 
Figure 29), suggesting that TNF-α might induce post-translational modifications 
leading to Erg protein degradation. Erg mRNA levels appeared upregulated 10 hours 
after the addition of TNF-α, suggesting that this could cause the recovery in Erg 
protein expression after 24 hours of TNF-α stimulation (Chapter 3, Figure 28 A). 
However, this result was not statistically significant. 
 
 
 
Chapter 3, Figure 29. Erg mRNA is not downregulated by TNF-α. HUVEC were 
treated with TNFα (10 ng/ml). Cells were lysed after the indicated time points and 
mRNA was analysed for Erg expression. Erg mRNA expression is quantified relative 
to GAPDH and normalized against untreated HUVEC. n=4. 
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3.3.1.3 Analysis of Erg protein degradation in TNF-α stimulated 
cells 
Because Erg protein down-regulation is not mirrored by a down-regulation of Erg 
mRNA levels in the same experimental conditions, we hypothesised that TNF-α 
could act downstream to Erg transcription, possibly inducing Erg protein 
degradation. To test whether the TNF-α-induced Erg protein downregulation acts via 
a proteasome-mediated degradation, HUVEC were incubated with a proteosome 
inhibitor, MG-132 for 30 minutes, and then stimulated with TNF-α. If TNF-α-
induced a degradation of the Erg protein, MG-132 would be expected to rescue this 
effect. First, test experiments to optimize the conditions of MG-132 usage were 
performed. HUVEC were pretreated with different concentrations of this compound 
(1 and 10 µM), and Erg protein expression was assessed 4 hours after the addition of 
TNF-α (10 ng/ml) and in control cells. At this time point, MG-132 induced a dose-
dependent increase in Erg levels. Moreover, when used at the highest concentration, 
this compound increased Erg levels after just 30 minutes, suggesting the existence of 
a rapid physiological turnover of degradation and re-synthesis of the Erg protein. 
Unexpectedly, in both the TNF-α stimulated and control samples that were not 
treated with MG-132, Erg levels were found reduced at the final time point (Chapter 
3, Figure 30). This is indicative of an in vitro artefact, possibly due to activation of 
stress pathways. To overcome this issue, the experimental design was simplified and 
Erg protein levels were analysed by western blot 6 hours after the addition of TNF-α, 
since this time point is closer to the peak of Erg downregulation by TNF-α (see 
Chapter 3, Figure 28). Erg was significantly downregulated by TNF-α in the absence 
of MG-132. Interestingly, this effect was not only rescued by adding the MG-132 
compound, but MG-132 also increased Erg levels more than 2 fold when compared 
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to cells treated with control vehicle dimethyl sulfoxide (DMSO) only (Chapter 3, 
Figure 31). This result shows that the TNF-α-mediated Erg downregulation is 
induced by protein degradation. Moreover, as previously shown in Chapter 3, Figure 
30, the MG-132-mediated induction of Erg levels occurred in both cells stimulated 
with  TNF-α and in cells left unstimulated, confirming that Erg is finely regulated by 
a fast protein turnover of degradation and re-synthesis in resting cells. The pathways 
involved in the regulation of the Erg protein turnover under resting and pro-
inflammatory conditions still need to be investigated. 
 
 
 
Chapter 3, Figure 30. Erg protein degradation following TNF-α stimulation: 
optimization experiments. HUVEC were pre-incubated with DMSO or MG-132 (1 or 
10µM) for 30 minutes (time: 0), and then treated with TNF-α or left unstimulated for 
the indicated time. Erg expression is quantified relative to GAPDH and normalized 
against HUVEC treated with DMSO. n=2. 
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Chapter 3, Figure 31. Erg protein is degraded following TNF-α stimulation. HUVEC 
were pre-incubated with DMSO or MG-132 (10µM) for 30 minutes, and then treated 
with TNF-α or left unstimulated for the indicated time. Erg expression is quantified 
relative to GAPDH and normalized against HUVEC treated with DMSO. n=3. 
*P<0.05; **P<0.01; ***P<0.001 
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3.3.2 Erg expression is regulated in human chronic inflammatory 
disease 
3.3.2.1 Analysis of Erg expression in human atherosclerotic 
plaques 
Monocyte infiltration via endothelial ICAM-1 and VCAM-1 is a key event driving 
atherosclerosis.
10;229
 Since expression of ICAM-1 and VCAM-1 is up-regulated in 
atherosclerotic lesions, and our data indicate that these adhesion molecules are 
repressed by Erg, we speculated that Erg expression may be decreased at these sites. 
Analyses of human coronary arteries with eccentric atherosclerotic plaques from 5 
different patients showed that Erg was consistently expressed in non-lesional 
endothelium (Chapter 3, Figure 32 Ai, dotted arrows) but absent from EC over the 
shoulder region of the plaque, which actively recruits leukocytes (Chapter 3, Figure 
32 Bi, dotted arrows). As controls, nuclear and VWF staining confirmed the presence 
of endothelium in both areas (Chapter 3, Figure 32 Aii and Chapter 3, Figure 32 Bii, 
arrows). These results are in line with our data showing that loss of Erg results in 
increased ICAM-1 expression (paragraph 3.2.1) and with previously reported data 
showing increased leukocyte adhesion to Erg-deficient EC.
182 
Unexpectedly, Erg 
staining also detected a cellular infiltrate in the intima of the inflamed area (Chapter 
3, Figure 32 Bi). Although a proper control should be performed to prove it, this cell 
population resembles the morphology typical of macrophages. At present, no data is 
available in the literature to prove the expression of Erg in this cell type.
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Chapter 3, Figure 32. Erg expression in coronary artery endothelium inversely 
correlates with the presence of atherosclerosis (Experiment carried out by Joe 
Boyle). Sections from a human coronary plaque, labelled with anti-Erg (Ai, Bi), anti-
VWF (Aii, Bii) antibodies and nuclear stain. Erg is expressed in the endothelium 
over the unaffected part of the vessel (Ai, dotted arrows), but is lost in the 
endothelium above the necrotic core (Bi, dotted arrows). VWF, endothelial staining 
(Aii, Bii, arrows). Neg., isotype control (Aiii, Biii). Erg-positive cells, probably 
mononuclear cells, are also found in the cellular infiltrate inside the lesion (Bi, 
arrowheads). A diagram, showing the corresponding areas of the plaque, is shown 
(C). Scale bars = 100 μm. 40x objective. Image representative of  5 coronary plaques 
from five subjects. 
 
 144 
CHAPTER 4: DISCUSSION AND FUTURE 
PERSPECTIVES 
By acting as a barrier between blood and tissues, the vascular endothelium plays a 
crucial role in the initiation of the inflammatory response, and in the physiopathology 
of inflammatory diseases such as atherosclerosis. The chronic alteration of 
endothelial homeostasis can regulate profound and long-lasting phenotypic changes, 
involving regulation of gene expression. Pro-inflammatory cytokines are crucial 
mediators of these events both in vivo and in vitro; TNF-α, for example, promotes 
leukocyte recruitment, coagulation and inflammation by up-regulating the expression 
of endothelial adhesion molecules such as E-selectin, ICAM-1 and VCAM-1.
12;32
 
Moreover, TNF-α also enhances the expression of chemokines such as IL-8, which 
exert a crucial role in the activation of leukocytes, inducing their binding to adhesion 
molecules on the activated endothelium.
40
 The pathways that lead to the up-
regulation of endothelial gene expression and to the alteration of endothelial 
homeostasis have been extensively investigated, and shown to involve the synergistic 
interaction of a small group of transcription factors, including NF-kB and AP-
1.
30;59;94
 In addition to up-regulating gene expression, proinflammatory cytokines 
also cause down-regulation of gene expression. Many genes are known to be down-
regulated by TNF-α, including molecules which are necessary to maintain 
endothelial homeostasis. The transcription factor Erg is one of these molecules.
 180;182
  
Other homeostasis regulators downregulated by TNF-α are the anti-inflammatory 
enzyme eNOS
230
 and the adhesion molecule ICAM-2,
180
 which interestingly are both 
transcriptional targets of Erg. Further understanding of homeostatic regulation in the 
endothelium will be extremely interesting and may help to identify new potential 
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targets that can be re-balanced during the activation of the endothelium by 
proinflammatory stimuli. 
In this PhD thesis, and in the related manuscript we have published this year,
181
 I 
have demonstrated for the first time that the transcription factor Erg inhibits 
cytokine-driven inflammation and NF-kB activity. I have shown that Erg can repress 
both basal and TNF-α-induced expression of ICAM-1, VCAM-1 and IL-8. 
Moreover, I showed that Erg represses NF-kB activity and phosphorylation. The 
relevance of these findings is corroborated by the fact that Erg represses both 
leukocyte adhesion in vitro and TNF-α-induced inflammation in an experimental 
mouse model.  Finally, in the current project an inverse correlation was found 
between Erg expression in the endothelium overlaying human coronary 
atherosclerotic plaques and the presence of inflammatory infiltration, thus identifying 
for the first time a potential link between Erg and atherosclerosis. 
 
4.1 Erg as a repressor of pro-inflammatory molecules 
The results reported here show that the transcription factor Erg acts as a repressor of 
constitutive expression of pro-inflammatory genes in EC. Recently Yuan et al 
showed that Erg represses IL-8 expression.
182
 Our results support these findings, 
since in the present investigation IL-8 mRNA levels are reduced in Erg over-
expressing HUVEC. However, Erg has a broader effect in repressing the basal 
expression of pro-inflammatory molecules, which is not restricted to IL-8. Indeed, 
Erg inhibits the constitutive expression of ICAM-1 and VCAM-1 (Chapter 3, Figure 
6), adhesion molecules that play a crucial role in inducing leukocyte arrest to EC. For 
the purpose of this PhD thesis, the investigation of the Erg repression of pro-
inflammatory targets has been focused on the ICAM-1 molecule. 
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Erg represses both ICAM-1 mRNA and protein levels, as well as ICAM-1 surface 
expression (Chapter 3, Figure 6 B, Figure 7, Figure 3). This suggests that this 
repression is functional, since cellular ICAM-1 can only exert its biological functions 
when expressed on the cell membrane. Endothelial cell phenotypes can be different, 
depending upon their vascular bed of origin. However, the expression of adhesion 
molecules such as ICAM-1 and VCAM-1 has been previously reported to be similar 
in unstimulated cells of venous and arterial origin.
231
 Not surprisingly, data from the 
current project show that ICAM-1 basal levels are repressed in both HUVEC 
(Chapter 3, Figure 7) and HCAEC (Chapter 3, Figure 8), which are respectively 
derived from venous and arterial endothelial beds. Erg over-expression exerts 50% 
higher repression on ICAM-1 levels in HCAEC compared to HUVEC. Interestingly, 
this is inversely proportional to the fold change in Erg levels previously reported for 
these 2 cell types in resting conditions: Erg mRNA expression in HUVEC is double 
when compared to HCAEC.
182
  
The mechanisms through which Erg inhibits the basal expression of pro-
inflammatory genes still have to be fully characterized. Data from the current 
investigation show that ICAM-1 is repressed by Erg at the transcriptional level. NF-
kB has been implicated in constitutive endothelial expression of genes such as P-
selectin
221
 and ICAM-2.
180
 Transcription induced by basal NF-kB seems to play a 
role in the Erg mediated repression of ICAM-1. Basal NF-kB activity, measured with 
a luciferase assay, is repressed in Erg over-expressing cells (Chapter 3, Figure 15). 
Moreover, the increase in ICAM-1 levels following Erg inhibition is rescued by 
treatment with the NF-kB inhibitor Bay-117085 (Chapter 3, Figure 5). By repressing 
IkBα phosphorylation and degradation, Bay-117085 has been shown to repress NF-
kB activity and the NF-kB-induced expression of adhesion molecules such as ICAM-
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1, as well as inflammation in vivo.
223
,
232
 However, because this compound might 
have some non-specific effects on other pathways,
223
 the experiment performed with 
Bay-117085 should be confirmed by inhibiting NF-kB using a different approach. 
For example, an adenovirus encoding a non-phosphorylable form of IkBα (IkBα 
super-repressor
233;234
) could be used to repress NF-kB in a more specific way, to 
confirm the data reported in this study. Moreover, other mechanisms leading to 
repression of basal ICAM-1 by Erg might involve epigenetic and chromatin structure 
modifications. This would eventually determine an inhibition of the transcriptional 
machinery on the ICAM-1 promoter. Erg has been shown to interact with the 
methyltransferase ESET,
235
 and might therefore exert its transcriptional repression by 
recruiting this and/or other epigenetic repressors to the ICAM-1 promoter. Ongoing 
work from another PhD project in our group is currently focused on the investigation 
of these mechanisms regulating the ICAM-1 basal repression by Erg, with particular 
interest on the ETS and NF-kB sites present on the ICAM-1 promoter. 
 
4.2 Erg as a repressor of TNF-α-induced expression of pro-
inflammatory molecules  
TNF-α is a well known pro-inflammatory molecule that plays a crucial role in the 
activation of pro-inflammatory pathways such as NF-kB, in the upregulation of 
adhesion molecules and chemokines, and in the pathophysiology of chronic 
inflammatory diseases. Because of these reasons, in the last decade this molecule has 
been a central focus of basic and clinical research. The present investigation has 
successfully identified the transcription factor Erg as a new transcriptional repressor 
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of TNF-α-induced pro-inflammatory gene expression, recognizing NF-kB as a target 
pathway (see next paragraph). 
In the present work, Erg over-expression has been shown to repress the TNF-α-
induced expression of ICAM-1, VCAM-1 and IL-8, as well as TNF-α-induced NF-
kB activity. Because Erg is down-regulated by TNF-α (discussed below) and by 
other pro-inflammatory stimuli,
182
 these data suggest that a future therapeutic 
approach specifically targeted to the area of inflammation might restore endothelial 
homeostasis by rescuing the cytokine-induced EC activation.  
Although the detailed investigation on the Erg-mediated repression of the TNF-α 
induction of VCAM-1 and IL-8 would be of particular interest, ICAM-1 was chosen 
as molecular target to understand the specific molecular mechanisms behind the Erg 
mediated pro-inflammatory gene repression. This is because of the higher and very 
significant degree of repression exerted by Erg on this molecule (Chapter 3, Figure 
10). Moreover, being the ICAM-1 promoter very well characterized, and because it 
contains a number of potential ETS binding sites, the analysis of the Erg repression 
on this adhesion molecule was chosen as a promising model of study. For the same 
reason, among these 3 pro-inflammatory molecules, ICAM-1 was chosen to measure 
the Erg mediated repression at the mRNA, transcriptional, and protein level. Erg 
represses the TNF-α-induced ICAM-1 expression in both HUVEC and HCAEC, with 
a higher level of repression in arterial EC. As discussed in the paragraph above, this 
could be due to the different levels of basal Erg expression in these cells. This is 
fascinating, considering the development of a therapeutic approach aimed to up-
regulate Erg levels in arteries of patients affected by chronic inflammatory diseases 
such as atherosclerosis or rheumatoid arthritis. However, no published data is 
available at the moment comparing the Erg levels in different EC stimulated with 
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TNF-α. This would be an interesting study to start describing the anti-inflammatory 
effects of Erg in different endothelial beds. Moreover, high throughput microarray 
analysis performed on TNF-α stimulated Erg over-expressing cells from different 
vascular beds might highlight differences in the expression profile of pro-
inflammatory molecules regulated by this transcription factor. This study might be 
extended to comparisons between microvasculature and large arteries. Because the 
latter are more prone to insults due to chronic inflammatory diseases such as 
atherosclerosis, this analysis might be helpful to identify pro-inflammatory 
molecules specifically downregulated by Erg  in such pathologies. 
4.3 Erg as a repressor of TNF-α induction of NF-kB 
4.3.1 Erg repression of NF-kB activity 
An important finding presented in this PhD thesis is the Erg mediated inhibition of 
the NF-kB cytokine-induced activation. Erg represses NF-kB activity in HUVEC, 
preventing TNF-α to induce NF-kB transcriptional activity. As shown in Chapter 3, 
Figure 15, treatment with AdErg inhibits the NF-kB transactivation potential to basal 
levels. Interestingly, a similar  degree of repression is also exerted by Erg on the 
TNF-α-induced ICAM-1 transcriptional activity (Chapter 3, Figure 13), suggesting 
that Erg plays a major role in repressing the promoter activity of this adhesion 
molecule by repressing NF-kB. As shown in Chapter 3, Figure 15, the sequence of 
the NF-kB luciferase reporter adopted in this study and previously elsewhere
214
 
contains 4 NF-kB binding sites recognized by bioinformatic analysis, which 
cooperate to drive luciferase transcription by amplifying the NF-kB-mediated 
signaling.  
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4.3.2 Erg regulation of IkBα turnover 
The results presented in this PhD thesis suggest that Erg blocks NF-kB activity 
through multiple mechanisms. Erg over-expression does not prevent IkBα from 
being degraded after 30 minutes of TNF-α stimulation, but causes increased IkBα 
resynthesis over 2 hours of TNF-α treatment (Chapter 3, Figure 16). IkBα synthesis 
is under the control of NF-kB p65, creating a negative feedback loop: newly 
synthesized IkBα binds NF-kB in the nucleus and directs the complex back to the 
cytoplasm, a mechanism that controls the inflammatory response.
44;138
 Thus, it is 
possible that Erg inhibits NF-kB activity partly by increasing its quenching by IkBα. 
NF-kB p50/p65 nuclear translocation was not affected by Erg over-expression after 
30 minutes of TNF-α stimulation, neither was the amount of p65 bound to the 
proximal ICAM-1 promoter following TNF-α stimulation in cells transduced with 
AdErg (Chapter 3, Figure 18). This suggests that the canonical mechanism of NF-kB 
regulation is not regulated by Erg. Moreover, this shows that the Erg-mediated 
repression of NF-kB does not depend on the displacement of p65 from the proximal 
promoter region of ICAM-1, which contains a composite NF-kB/ETS binding 
sequence (Chapter 1, Figure 4). The absence of p65 displacement by Erg from the 
ICAM-1 promoter in TNF-α stimulated cells should be confirmed using a 
quantitative chromatin immunoprecipitation (CHIP) assay, since this experimental 
system preserves the endogenous intracellular molecular structures that might be 
disrupted in an in vitro ELISA assay. Moreover, longer time-courses on TNF-α 
stimulated Erg over-expressing HUVEC might uncover partial contributions due to 
altered shuttling and/or promoter binding of p50 and p65. The NF-kB nuclear and 
cytoplasmic translocations are indeed highly dynamic,
220
 and the effects exerted by 
Erg in this scenario might not be detectable after 30 minutes of TNF-α treatment.  
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4.3.3 Erg regulation of p65 phosphorylation 
Intriguingly, Erg over-expression leads to the inhibition of TNF-α–induced p65 
phosphorylation at Ser-536, a key modification that enhances NF-kB transactivation 
potential, and the NF-kB induction of key pro-inflammatory markers such as IL-8 
(Chapter 3, Figure 19, 
159;162;165
). This result provides at least a partial explanation of 
the mechanism exerted by Erg to repress NF-kB activity. The relevance of this 
finding should be further assessed by over-expressing a phospho-mimetic Ser-536 
p65 construct
159
 to rescue the Erg-mediated inhibitory effect on this residue. The p65 
phosphorylation at Ser-536 has been shown to be relevant to induce the association 
between p65 and CREB-binding protein/p300.
168
 Therefore, Erg could reduce the 
interaction between p65 and CBP/p300 by inhibiting p65 phosphorylation at Ser536. 
Different kinases have been shown to induce phosphorylation of Ser536.
159
 Two of 
them, namely IKKβ and TBK1, were highlighted as putative Erg targets in a 
microarray on Erg deficient HUVEC compared with control cells (Birdsey G. and 
Randi A.M., submitted to Blood). The regulation of these two kinases by Erg was 
assessed at the mRNA level. Of these two molecules, only IKKβ was regulated after 
both Erg over-expression and downregulation (Chapter 3, Figure 20). However, 
further assessment of IKKβ regulation at the protein level did not reveal any Erg 
mediated effect (Chapter 3, Figure 21). This indicates that endogenous feedback 
mechanisms compensate the Erg effect by restabilizing TBK1 protein levels, and that 
other kinases, or eventually the activation state of these molecules, might be the 
target of Erg acting on the p65 phosphorylation state.  
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4.3.4 Erg, NF-kB and beyond 
Interestingly, the two effects of Erg on the NF-kB pathway described in the above 
paragraphs, such as the increased IkBα turnover and the repression of p65 
phosphorylation, may be linked. Increased IkBα levels were reported in cells 
overexpressing a p65 mutant, in which Ser536 was mutated to alanine, thus 
preventing phosphorylation; this suggests that this post-translational modification 
regulates IkBα levels.163 These results raise the possibility that Erg could regulate 
IkBα levels by interfering with p65 Ser536 phosphorylation. 
Overall, I propose that Erg inhibits NF-kB activity in a dual way, by repressing p65 
ability to transactivate its target genes and by inducing the expression of the NF-kB 
inhibitor IkBα after TNF-α stimulation. Finally, I cannot rule out that Erg may affect 
nuclear translocation, DNA binding, and/or posttranslational modifications of other 
NF-kB subunits; however, their role on ICAM-1 transcription appears to be less 
critical.
78;96;99;100
 
If the contribution of transcriptionally active NF-kB in the transactivation of the 
ICAM-1 promoter has been extensively demonstrated in a variety of cells,
30;91;95;96
 in 
EC the effect of other TNF-α-induced pathways such as Erk 1/2 and p38MAPK 
remains unclear.
97;98
 A study aimed to measure the TNF-α induction of the ICAM-1 
promoter following AdErg transduction in HUVEC would clarify the role of the 
MAPK/Erk pathway in this cell type. This experiment would be performed in Erg 
deficient HUVEC over-expressing the ICAM-1 luciferase reporter and treated with 
the MAPK/Erk inhibitors PD98059 and SB203580. These two compounds have been 
respectively used to study the role of Erk 1/2 and p38MAPK to induce ICAM-1 
expression in TNF-α stimulated EC.236 If Erg depletion results in an induction of the 
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ICAM-1 reporter, and this is rescued by Erk 1/2 and p38MAPK inhibition, the 
MAPK/ERK pathway would play a role in the transactivation of the ICAM-1 
promoter. If this investigation gives positive results, further examination of the 
ICAM-1 promoter might indicate the sites responsive to the activation of these 
pathways, and a selective mutational analysis of TNF-α responsive sites  might 
uncover the functionally relevant ones. 
4.4 Erg as a repressor of inflammation 
In vivo, AdErg treatment results in a significant decrease of inflammation in a TNF-α 
–dependent mouse model. Erg over-expression leads to a reduction of the TNF-α-
induced paw swelling in a dose dependent way, almost rescuing the inflammatory 
response. This effect is lost using low doses of Erg adenovirus, suggesting that the 
Erg mediated effect is dose dependent (Chapter 3, Figure 27 B). This result is 
encouraging in terms of exploiting Erg’s anti-inflammatory properties 
therapeutically. Interestingly, the mechanism we have proposed for Erg repression of  
acute inflammation in vivo is supported by the reduction of the pro-inflammatory 
markers ICAM-1 and MPO (Chapter 3, Figure 27 C). This indicates that ICAM-1 
plays a role in the recruitment of monocytes, important players in the early stages of 
inflammation which infiltration into the TNF-α injected tissue is repressed by Erg. In 
vitro leukocyte adhesion experiments also support these data, since the arrest of 
leukocytes to HUVEC was found being repressed in Erg over-expressing cells 
(Chapter 3, Figure 22). Further in vitro studies performed on flow conditioned EC 
might uncover a potential role for Erg in repressing other phases of the leukocyte 
adhesion cascade, as rolling and transmigration (see introduction, paragraph 1.3.1), 
and their functional relevance could be tested using specific blocking antibodies. In 
parallel, a screening of other adhesion molecules might be performed in vivo on the 
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same paw swelling mouse model discussed above, starting with the assessment of the 
pro-inflammatory genes VCAM-1 and IL-8 , the most likely to be repressed by Erg. 
Having demonstrated the relevance for Erg in repressing NF-kB in vitro (discussed 
in paragraph 4.3), it would be interesting to evaluate whether this pathway is 
repressed by Erg in vivo. If it is, the subsequent analysis might be focused on 
understanding whether similar molecular mechanisms within this pathway are 
regulated by Erg in vitro and in vivo. The former hypothesis should be assessed by 
the induction of paw swelling in a NF-kB enhanced green fluorescent protein 
(EGFP) reporter mice, a model already in use by other groups.
237
 If the activation of 
NF-kB is repressed by Erg in this mouse model, further analysis with antibodies 
against phosphorylated forms of NF-kB (including p65 phospho-Ser-536) might be 
carried out. 
The results discussed here might be subsequently developed  in a more complex 
model of characterization, that would lead to a better understanding of how Erg 
represses inflammation in vivo. Of particular interest, a conditional endothelial Erg 
knockout mouse line has been recently generated in our lab (Birdsey G. and Randi 
AM.). Since Erg represses the basal expression of adhesion molecules (see paragraph 
3.1.2) and leukocyte adhesion in non stimulated EC,
182
 these molecular and 
functional readouts of inflammation could be studied in this mouse, which might be 
prone to develop early signs of chronic inflammation due to Erg depletion. 
Moreover, coronary arteries of lipid fed ApoE knockout mice might be transduced 
with the Erg adenovirus to understand if Erg plays a role in repressing chronic 
inflammation, focusing on the degree of the atherosclerotic lesions’ development. To 
achieve this, intra-coronary implants, coated with anti-adenovirus antibodies, could 
be developed and used as in previous studies
238
 to deliver the Erg vector in a site-
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specific manner, with relatively high local expression levels, and with no distal 
spread from the inflamed area of interest. Moreover, the opposite experiment might 
be performed on ApoE knockout mice crossed with the inducible endothelial specific 
Erg knockout mice, to test whether Erg is involved in the development of 
atherosclerosis. Because in this mouse model the excision of the Erg allele can be 
determined at a precise temporal stage, the ablation of the Erg protein might be 
associated with different readouts during the development of the atherosclerotic 
plaque. This experiment would help understanding if the protection exerted by Erg in 
atherosclerosis plays a role only in the early stages of the disease, as leukocyte 
adhesion and infiltration, or also in the later stages, when events such as foam cell 
activation and plaque remodeling are involved. If this this second hypothesis is true, 
the focus of this research could be extended to other Erg positive cell types, such as 
macrophages, so far not yet characterized in terms of Erg expression and function.     
4.5 Regulation of Erg expression during inflammation 
Erg is expressed at high levels in resting EC and is constitutively active, both as an 
activator and as a repressor of transcription. As discussed above, Erg over-expression 
inhibits the TNF-α-induced up-regulation of ICAM-1, VCAM-1 and IL-8 as well as 
NF-kB activation, whilst pro-inflammatory agents down-regulate expression of Erg 
in EC.
180;182
 This suggests that endothelial Erg expression is down-regulated by pro-
inflammatory signals in order to allow expression of pro-inflammatory genes through 
the NF-kB pathway. To begin to investigate the relevance of this pathway in disease, 
human atherosclerotic plaques were studied. Erg expression was found to be lost 
from the endothelium overlaying the active shoulders of human coronary plaques, 
characterized by endothelial activation and macrophage infiltration (Chapter 3, 
Figure 32). This finding, the first associated with human disease, corroborates the in 
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vitro data showing that Erg represses expression of ICAM-1 and VCAM-1 and 
inhibits leukocyte adhesion. The expression of ICAM-1 and VCAM-1 is increased 
on the endothelium overlaying inflamed areas of plaque, and both have been 
implicated in the pathogenesis of atherosclerosis.
229
 Thus, Erg may have a role in 
protection from atherosclerosis via regulation of monocyte infiltration.  
Since inflammatory and pro-atherogenic stimuli down-regulate Erg expression and 
loss of Erg expression is required for pro-inflammatory signaling in EC, 
understanding how Erg expression is regulated is an essential step towards validating 
Erg as a target for therapeutic intervention. Erg mRNA levels are not decreased by 
TNF-α stimulation (Chapter 3, Figure 29), suggesting that TNF-α might destabilize 
Erg at the protein level. The ubiquitin-proteasome system is the major pathway for 
intracellular protein degradation in mammalian cells,
239
 therefore this machinery was 
inhibited with the proteasome inhibitor MG-132 to assess whether TNF-α down-
regulated Erg by inducing its protein degradation. In support of this hypothesis, Erg 
downregulation by TNF-α was blocked by MG-132 (Chapter 3, Figure 31). The 
novelty of this finding resides in the identification of an endogenous protective Erg-
dependent pathway in ECs, which could be manipulated pharmacologically for the 
prevention of inflammatory diseases. To confirm that Erg down-regulation is due to 
proteosomal degradation, this experiment could be repeated with other proteasome 
inhibitors, such as MG-262. Furthermore, Erg ubiquitination might be specifically 
studied by performing reciprocal immunoprecipitations with Erg and anti-ubiquitin 
antibodies in TNF-α stimulated cells. The precise time of Erg ubiquitination and 
degradation would be identified by performing time-courses in TNF-α stimulated 
cells, and would allow to focus on the activation of specific upstream pathways. 
Finally, Erg has been previously shown to interact with the yeast ubiquitin-
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conjugating enzyme UBC9.
240
 Mammalian UBC9 is required for rapid degradation 
of other transcription factors such as the E2A proteins  E12 and E47. Therefore, by 
using siRNA against UBC9 it might be tested whether UBC9 is involved in Erg 
degradation by TNF-α. This information might be important for a future design of 
Erg constructs which are resistant to protein degradation by TNF-α. 
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APPENDIX A: ABBREVIATIONS  
AdErg: adenovirus encoding for p55 Erg 
AdLacZ: adenovirus encoding for β-galactosidase 
Ang: angiotensin 
Apo-E: Apolipoprotein E 
BCECF: 2′,7′-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein 
BCR: B-cell receptors 
BP: base pairs 
CBP: CREB-binding protein 
ChIP: chromatin immunoprecipitation 
COX: cyclooxygenase 
CTA: carboxy terminal transcriptional activation 
Ctl: control 
DAB: 3,3-diaminobenzidine tetrahydrochloride 
DMSO: dimethyl sulfoxide 
DTT: dithiothreitol 
EC: endothelial cells  
ECGF: Endothelial Cell Growth Factor  
EDB: ETS DNA binding domain  
Erg: Ets related gene 
Erk: extracellular signal-regulated kinase 
ETA: ETS transcriptional activation domain 
ETS: E26 transformation specific 
FBS: fetal bovine serum  
GB: genebloc 
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GPCR: G protein-coupled receptors 
GSK: glycogen synthase kinase 
H&E: haematoxylin and eosin 
HBSS: hanks' balanced salt solution 
HCAEC: human coronary artery endothelial cells 
HDAC-1:histone deacetylase 1 
HO-1: heme oxigenase-1 
HRP: horseradish peroxidise 
HSP: heat shock protein 
HUVEC: human umbilical vein endothelial cells 
ICAM-1: intercellular adhesion molecule-1 
ID: the inhibitory domain 
IFN: interferon 
Ig: immunoglobulin 
IkB: inhibitor of kB 
IKK: inhibitor of kB kinase 
IL-1R: IL-1 receptors 
IL-8: interleukin 8 
IMDM: iscove's modified Dulbecco's medium 
IP: immunoprecipitation 
ITR: inverted terminal repeat 
kDa: kilodalton  
LDL: low-density lipoproteins 
LFA-1: lymphocyte function-associated antigen 1 
LPS: lipopolysaccharide 
 160 
mAbs: monoclonal antibodies 
MAC1: macrophage antigen 1 
MALDI QTOF: matrix-assisted laser desorption/ionization–quadrupole time-of-
flight 
MCP-1: monocyte chemoattractant protein-1  
M-CSF: macrophage colony-stimulating factor 
MEKK3: MAP/ERK kinase kinase 3 
MLC: myosin-light-chain 
MMP: metalloproteinase 
MOI: multiplicity of infection 
MPO: myeloperoxidase 
MSK1: stress-activated protein kinase-1 
NADPH: Nicotinamide adenine dinucleotide phosphate-oxidase 
NBD: NEMO-binding domain 
NF-kB: Nuclear factor kappa B 
NK: natural killer 
NLS: nuclear localization sequence 
NOS: NO synthase 
NRF: NF-kB repressing factor 
NRT: negative regulatory transcriptional activation domain 
OCT-1: and octamer-1 
pAbs: polyclonal antibodies 
PCR: Polymerase chain reaction 
PFA: paraformaldehyde 
PFU: plaque forming units 
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PI3K: phosphoinositide 3-kinase 
PK: protein kinase 
PKAc: catalytic subunit of PKA  
PNT: pointed domain 
RD: and the repressor domain 
RHD: Rel homology domain 
RIP: receptor-interacting proteins 
ROS: reactive oxygen species  
RSK1: serine/threonine kinase ribosomal S6 kinase 1 
SDS-PAGE: sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TAD: transactivation domain 
TAK1: TGFβ-activated kinase-1 
TBK1: TRAF family member associated (TANK)-binding kinase 1 
TCR: T-cell receptors 
TEM: transendothelial migration 
TF: tissue factor 
TLR: Toll-like receptors 
TNFR: TNF receptor 
TRADD: TNFR-associated death domain 
TRAF: TNF receptor associated factor 
UTR: untranslated regions 
VCAM-1: vascular cell-adhesion molecule 
VEGFR: vascular endothelial growth factor receptor 
VLA4: very late antigen-4 
VSMC: vascular smooth muscle cells 
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VWF: von Willebrand factor 
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